$VSQTF Intends to Acquire V2 Games; Shares Surge

Established mobile games studio is the latest addition to the VST portfolio of technology companies spanning core competencies in Blockchain, Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film

VANCOUVER, BRITISH COLUMBIA, CANADA (February 14, 2018) – Subject to all requisite regulatory approvals, Victory Square Technologies Inc. (“Victory Square” or the (“Company”) (CSE:VST) (OTC:VSQTF) (FWB: 6F6) will acquire 100% percent of all issued and outstanding shares of V2 Games Inc. (“V2 Games”), an established mobile games studio with a track record of highly-rated entries on the Apple Store listings, for $2,000,000 CAD in total consideration (the “Purchase Price”).

Pursuant to a definitive share purchase agreement to be executed between the Company and the shareholder(s) of V2 Games (the “Share Purchase Agreement”), the Purchase Price will be paid and satisfied by the Company through the issuance of 1,030,928 common shares in the capital of the Company (the “Consideration Shares”) to the shareholder(s) of V2 Games at a deemed issue price of $1.94 per Consideration Share. The deemed issue price represents the closing price of the common shares of the Company on the Canadian Securities Exchange at the end of trading on February 13, 2018, the trading day preceding this news release announcing the acquisition, less a discount of 10%. In accordance with the terms of the Share Purchase Agreement, the Consideration Shares shall be subject to resale restrictions, which permit 8% of the Consideration Shares to be eligible to be free trading four months from the date of issuance to satisfy the statutory hold period and a further 8% every three months thereafter until the final balance of Consideration Shares is eligible to be free-trading in approximately three years’ time. The Share Purchase Agreement also contains standard representations, warranties and covenants for transactions of this nature.

“Given the full and total philosophical alignment between our companies, we are of course excited and proud to announce the acquisition of V2 Games, a leading mobile games developer based in Vancouver, Canada,” said Victory Square Chief Executive Officer Shafin Diamond Tejani. “Just as we’ve committed to partnering with high quality entrepreneurs and management teams that drive long-term shareholder value, V2 Games supports top tier teams in the gaming industry with a view to unlocking their potential by providing them with seed capital and the necessary strategic expertise needed to scale their gaming ventures. As entrepreneurs ourselves, we are impressed with the V2 Games model, along with the depth of knowledge of the management team.”

Started as a game development and publishing studio, V2 Games was the first Canadian company to license the iconic PAC-MAN IP as a mobile game. The company has a rich operating history of licensing large IPs, including PAC-MAN, Hello Kitty, the NFL and the NBA. Fueled by its success in the mobile gaming market, V2 Games evolved as a company and began investing its returns into other companies within the gaming space.

“This acquisition not only allows us to maintain our core competency of identifying early investments in gaming assets, but firmly puts us ahead of schedule in our pursuit to be a key strategic investment hub with which entrepreneurial video game teams will continue to place their faith in order to bring their creations to life,” said Sam Chandola, the award-winning CEO of V2 Games. “Through Victory Square’s expertise in the public markets, we will now be able to offer top-tier opportunities in the gaming market to retail investors, while also leveraging the strength of the public markets to facilitate new financing opportunities for the gaming industry.”

Apart from a focus on the established western gaming market, V2 Games has also made significant investments in emerging markets in the gaming industry, with the company having setup subsidiary operations in India as early as January 2016.

“Post-acquisition, Victory Square will seamlessly integrate V2 into our fast-growing portfolio of disruptive technology investments,” said Tejani. “Through a combination of management, legal, operational, and marketing expertise, we will assist the V2 management team in accelerating their business and positioning them as an emerging leader in the mobile games market.”

V2 Games CEO Chandola is also a recipient of many entrepreneurial awards, including the BC Business Top 30 under 30 award (2014), RBC Top 75 Canadian Immigrant (2015), and the TMX Next 150 (2017). With a keen eye on the future, he is also at the forefront of exploring exciting new opportunities in the world of gaming brought by new technologies such as Blockchain.

“Victory Square’s experience as an early promoter of Blockchain will help support our new and exciting initiatives to explore the intersection of Gaming and Blockchain,” added Chandola. “V2 Games is one of the first traditional gaming companies that is investing heavily in Blockchain, and Victory Square is an ideal partner in that regard.”

Recent V2 Games’ investments include Flow, an equity crowdfunding platform for games powered by Blockchain, and Shape Immersive, an AR Blockchain company that develops state of the art products that bridge the experience between the physical and virtual worlds.

For further information about the Company, please contact:

Investor Relations Contact – Prit Singh

Email: prit@victorysquare.com

Telephone: 905-510-7636

Media Contact – Howard Blank, Director

Email: howard@victorysquare.com

Telephone: 604-229-3594

ABOUT VICTORY SQUARE TECHNOLOGIES INC.

Victory Square Technologies is a blockchain-focused venture builder that funds and empowers entrepreneurs to implement innovative blockchain solutions. Victory Square portfolio companies are disrupting every sector of the global economy including Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. Victory Square has a proven process for identifying game-changing entrepreneurs and providing them with the partners, mentorship and support necessary to accelerate their growth and help them scale globally. For more information, please visit www.victorysquare.com.

ABOUT THE CANADIAN SECURITIES EXCHANGE (CSE)

The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets.

FORWARD-LOOKING INFORMATION

This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Victory Square. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square, including future plans. Although Victory Square believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Victory Square can give no assurance that they will prove to be correct. Forward- looking statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

$PBIO Enters Co-Marketing, Distribution Agreement with ISS, Inc.

ISS High Pressure Optical Cell Integrated with PBI Automated High Pressure Instrument: Combination Results in Unique Analytical System with Potential to Significantly Improve and Enhance Biopharmaceutical Drug Discovery and Development

SOUTH EASTON, MA / February 14, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, high pressure-based instruments and related consumables for the worldwide life sciences industry, and ISS, Inc., a designer and manufacturer of advanced scientific instrumentation for over 30 years, today announced a two-year, global co-marketing and distribution agreement.

Thousands of scientists worldwide routinely use a powerful analytical method called optical spectroscopy to generate information on the composition of biological molecules, such as proteins, RNA, and DNA. Information obtained is used for many purposes, including the design and development of new drugs, diagnostics, vaccines, and disease preventive strategies. Interfacing innovative new capabilities with the optical spectrometer offers the potential to generate more, sometimes even critical information for the scientist.

High pressure optical spectroscopy is increasing in popularity because it offers a unique and very effective way to look at molecular interactions. Unlike chemicals, which take time to mix and interact with a biological sample and whose use often produces uncontrollable irreversible changes, high pressure is instantaneous and homogeneous and the line between reversibility and irreversibility can be better controlled by controlling the amount and duration of the applied pressure. These features help research scientists understand how biological molecules interact and function – information that can be critical to the discovery and development of new and improved drugs and diagnostics.

Dr. Ben Barbieri, President of ISS, said, “ISS is a worldwide, leading provider of high pressure optical cell systems that can be interfaced directly to our spectrometers or utilized as stand-alone units with non-ISS instruments. The pressure required for the optical cell is currently generated by a manual, crank-operated, non-automatable pressure generator. We believe that replacing this manual crank pressure generator with the computer controlled HUB 440/880 pressure instruments from PBI could result in the ability to visualize biochemical reactions as they are happening in the pressure cell. The PBI pressure generators will also facilitate automated and significantly faster data collection. Such systems could potentially have a significant and far-reaching impact on drug development and other important areas of biomedical research worldwide.”

Dr. Alexander Lazarev, Vice President of R&D for PBI, said, “Our pressure-generating instruments are widely used to control enzymatic activity and manipulate protein conformation in biomarker discovery, quality control of biopharmaceuticals, and biophysical studies of protein drug targets. Currently, our customers can only visualize irreversible molecular changes remaining after samples are retrieved from a pressure chamber. However, interfacing the PBI HUB 440/880 pressure generators with the ISS high pressure optical cell system will allow scientists to visualize and measure pressure effects on molecular interactions and protein conformation as the reactions are taking place in the optical cell – in real time. This novel capability should help scientists better understand how proteins function and interact with other biomolecules, which is critically important in the development of better, more effective diagnostics and pharmaceuticals.”

Dr. Nate Lawrence, Vice President of Marketing and Sales for PBI commented, “We are very pleased to enter into this co-marketing and distribution agreement with ISS. The unique combination of PBI’s high pressure generators and ISS’s high pressure optical cell system is expected to greatly benefit scientists in academic institutions, industry, and government who study biological samples and processes at the molecular level.”

Dr. Lawrence continued, “This new ISS/PBI instrument system will be unveiled at the annual Biophysical Society Meeting (BPS), which begins on February 17^th in San Francisco, CA. PBI and ISS have exhibit booths at the meeting, where the new instrument system will be showcased, and its cutting-edge applications presented to the more than 7,000 scientists expected to attend. Both companies will share their extensive customer contact lists to broadly promote this powerful combination of technologies to scientists worldwide, which we believe will result in increased sales in 2018 and beyond.”

About ISS, Inc.

Since 1984, ISS has been committed to the design and development of innovative, highly-sensitive scientific instrumentation for research, clinical, and industrial applications. ISS instrumentation is used by scientists working in the life sciences, drug discovery, material sciences, and basic physical-chemical research applications. ISS instruments have been installed in university, government, and industry laboratories worldwide. In the United States, customers include – among others – academic institutions, pharmaceutical and biotech companies, the Mayo Foundation, the VA Administration, the National Institutes of Health, Oak Ridge National Laboratories, and the National Aeronautics and Space Administration (NASA).

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward-Looking Statements

Statements contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Investor Contacts:

Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.
Nathan P. Lawrence, Ph.D., VP of Marketing and Sales (508) 230-1828 (T)
Beniamino Barbieri, Ph.D., President ISS, Inc. (217) 359-8681 (T)

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

$PVOTF Provides Update Covering Recent Achievements and Activities

February 14, 2018

• Update highlights proposed acquisitions, product development and growing IP portfolio
• Three new patent filings join established global rights to other patented technologies
• Innovative transdermal delivery technology increases bioavailability of cannabinoids
• Global cannabis market projected to reach $31.4 billion by 2021

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) has provided investors an update covering a number of recent achievements and ongoing activities, including the company’s proposed acquisitions of ERS Holdings, LLC and Thrudermic, LLC; its ongoing product development efforts; its growing IP portfolio; its termination of a previously announced standstill agreement; out-licensing of its IP; and its engagement of an established European distribution partner (http://cnw.fm/sB649). In a news release, Dr. Patrick Frankham, CEO of Pivot, stated, “We are overwhelmed by interested companies who now understand that derivatives and superior formulations will improve cannabis product experience and healthy outcomes.”

Based in Vancouver, Canada, Pivot Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using proprietary drug delivery platform technologies. By developing and commercializing a number of pharmaceutical-grade formulations for cannabinoid-based consumer health care products, Pivot Pharmaceuticals is positioning itself to capitalize on the impressive growth of the cannabis market. According to market research company Brightfield Group, the marijuana market will experience a CAGR of 60 percent to reach $31.4 billion by 2021 (http://cnw.fm/8Kg16).

As part of its overall growth strategy, Pivot Pharmaceuticals recently filed three provisional patents for cannabinoid-based product delivery with the U.S. Patent and Trademark Office, according to a company press release (http://cnw.fm/J3CsB) issued on February 1, 2018.  Its three patents cover:

• Transdermal nanotechnology delivery of cannabis using patches and creams
• Mucus topical cannabis delivery through buccal, nasal, vaginal and anal areas using a gel, mouthwash or suppository
• Inhalation delivery of cannabis for topic or systemic applications

These latest provisional patent filings join an established number of global rights to topical, oral, transdermal, food and beverage patented technologies that Pivot has already secured.

A case in point is Pivot’s recent acquisition of the BiPhasix™ Transdermal Drug Delivery technology for the delivery of cannabinoids. Oral delivery of cannabinoids can produce inconsistent absorption efficiencies and unfavorable side effects, while topical delivery technologies often suffer from weak formulation issues. By contrast, transdermal delivery has greater potential to produce a more favorable outcome without the negative side effects and absorption issues. Another benefit of transdermal delivery is that it enables patients to apply medication over a prolonged period with fewer side effects than with other methods of delivery. The BiPhasix™ delivery system, thoroughly tested in clinical trials approved by the FDA and EMA, was demonstrated to enhance the bioavailability of drugs and to improve clinical outcomes.

Pivot Pharmaceuticals also created subsidiary Pivot Green Stream Health Solutions Inc. to focus on improving the bioavailability of cannabinoid-based pharmaceuticals. Pivot Green Stream will develop natural cannabinoid-based health products that qualify for the Natural Health Product (NHP) designation conferred by Health Canada.

In addition, Pivot has acquired the global rights from Solmic GmbH for the development and commercialization of the Solmic Solubilization Technology Platform. This formulation technology provides significantly higher bioavailability of active ingredients while masking unpleasant tastes and smells. This oral delivery platform greatly increases uptake of fat-soluble ingredients from the gut into the blood system, resulting in increased bioavailability.

The company has several products in its development pipeline which target cancer supportive care, pain and inflammation, dermatology and eye disease. They include PGS-N005, a cannabinoid-based topical cream to treat female sexual dysfunction. This formulation will treat hypoactive sexual desire disorder, aimed specifically at peri-menopausal, menopausal and post-menopausal women with a decline in sexual desire and response. It is estimated that up to 63 percent of women in the United States may be affected by this disorder, with the female sexual dysfunction market estimated to exceed $4 billion.

Pivot Pharmaceuticals has a seasoned management team with extensive clinical, product development, commercial and financial experience. The company has positioned itself to be a crucial vertical in the cannabis industry, with a focus on biotechnological development. As part of its business strategy, Pivot works with licensed producers (LPs) and licensed dealers (LDs) to bring new therapies to the market.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

• Medical Cannabis Payment Solutions (REFG) CEO Confident About Utah Cannabis Bill Success
• Marijuana Company of America, Inc. (MCOA) Executing a Strategy Aligned with Future Forces
• Earth Science Tech, Inc. (ETST) Launches High Grade Full Spectrum Cannabinoid Products

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$ETST Launches High Grade Full Spectrum Cannabinoid Products

February 14, 2018

• ETST intends to make 2018 its breakout year, seeks uplisting to the OTCQB Venture Market
• Company manufactures using European CO2 extraction process with organically grown, unfiltered industrial hemp
• ETST engages a new distributor to market revamped product line to major retailers, also adds several new members to its executive team

On February 13, Earth Science Tech, Inc. (OTC: ETST) officially launched its High Grade Full Spectrum Cannabinoids products and a corresponding marketing strategy, as the company detailed in a recent news release (http://nnw.fm/5NXIi). Additionally, it signed a distribution agreement with Mr. Checkout to market its revamped product line to major retailers and stores, such as Walmart, Target and Walgreens (http://nnw.fm/bBOg5).

The revamped line consists of industrial hemp product formulated as a cannabinoid complex, which is naturally occurring in the industrial hemp plant and is rich in terpenes and saponins. The company’s products are mixed, bottled and packaged in the U.S., and reorders are currently being accepted online. The line appears in modern and edgy packaging.

Based in Florida, ETST markets high-purity, high-grade hemp cannabidiol (CBD) oil. It is 100 percent natural and organic. The company has three wholly-owned subsidiaries: Earth Science Pharmaceutical markets low-cost, non-invasive medical devices for the detection of sexually transmitted diseases (STDs); Cannabis Therapeutics is an emerging biotechnology company; and KannaBidioiD focuses on the recreational space with its hemp and Kanna blends.

ETST recently strengthened its core executive team (http://nnw.fm/2BRYy) through the addition of Jill Buzan as chief sales officer, Wendell Hecker as chief financial officer and Gabriel Aviles as chief learning officer. The company expects the moves to foster bottom line growth in 2018.

In a news release, Nickolas S. Tabraue, COO and president of ETST, said, “Between appointing a new Chief Sales Officer, launching revamped industrial hemp products with fresh branding and marketing strategies, and our new distributor, Mr. Checkout, we are on track for a record-setting revenue month.” He added that the company intends to make 2018 its breakout year, for which it is laying a strong foundation in the first quarter.

The company also announced that it has completed the paperwork for its uplisting to the OTCQB Venture Market later this year.

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

• Medical Cannabis Payment Solutions (REFG) CEO Confident About Utah Cannabis Bill Success
• Pivot Pharmaceuticals Inc. (PVOTF) Provides Update Covering Recent Achievements and Activities
• Marijuana Company of America, Inc. (MCOA) Executing a Strategy Aligned with Future Forces

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CATB Edasalonexent Preserved Muscle Function, Substantially Slowed #DMD Progression

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new positive efficacy and safety results showing preservation of muscle function and sustained disease-modifying effects in boys with Duchene muscular dystrophy (DMD) in the MoveDMD trial open-label extension following 48 and 60 weeks of treatment with edasalonexent. Consistent improvements in all assessments of muscle function were observed after more than a year of oral 100 mg/kg/day edasalonexent treatment compared to the rates of change in the pre-specified control period for boys prior to receiving edasalonexent treatment. Additionally, supportive changes in non-effort based measures of muscle health were seen, with significant longer-term reductions in muscle enzymes and C-reactive protein (CRP), supporting the durability of edasalonexent treatment effects. Edasalonexent continued to be well tolerated with no safety signals observed in the trial. These data will be presented on Saturday, February 17, 2018, at 14:15 CET at the XVI International Conference on Duchenne and Becker Muscular Dystrophy in Rome, Italy, and detailed at future scientific conferences.

Catabasis plans to initiate a single global Phase 3 trial with edasalonexent in patients with DMD regardless of mutation type in the first half of 2018 with top-line results expected in 2020. Edasalonexent is a potential oral foundational therapy that is being developed for all patients affected by DMD.

“We are thrilled to see this preservation of muscle function and substantial slowing of disease progression in boys following more than a year of edasalonexent treatment. This effect has the potential to be extremely impactful for boys affected by Duchenne,” said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. “Building on the results previously reported for edasalonexent treatment in patients up to 36 weeks, these new data at 48 and 60 weeks show that edasalonexent continued to slow progression of the disease. We look forward to advancing edasalonexent in a single global Phase 3 trial later this year with the goal of improving the quality and length of life for those affected by Duchenne.”

“As this study matures and we see the effect of edasalonexent treatment through 48 and 60 weeks, it is compelling that all of the assessments of muscle function are demonstrating stabilization at an age when boys with DMD have a predictable decline,” said Richard Finkel, M.D., Chief, Division of Neurology, Department of Pediatrics at Nemours Children’s Health System and a Principal Investigator for the study. “Clinically meaningful changes are observed here. The coherence of these data is very promising and I look forward to continuing to investigate edasalonexent in the Phase 3 trial as a potential therapy for the many boys affected by this devastating disease.”

In Phase 2 and the open-label extension of the MoveDMD trial, a preservation of muscle function and slowing of DMD disease progression was seen in boys treated with edasalonexent compared to the rates of change during the control period prior to receiving edasalonexent. Through 60 weeks of treatment, the 100 mg/kg/day treatment group showed consistent and clinically meaningful improvements in rates of decline compared to rates of change during the control period across all four assessments of muscle function: the three timed function tests (10-meter walk/run, 4-stair climb and time to stand), as well as the North Star Ambulatory Assessment (NSAA), an integrated global assessment of muscle function. Control period changes were measured prior to boys receiving edasalonexent, either prior to Phase 2 or during Phase 2 prior to treatment in the open-label extension for those in the placebo group, for time periods averaging 39 weeks. In the 100 mg/kg/day treatment group, 16 boys commenced edasalonexent either at the beginning of Phase 2 or at the beginning of the open-label extension. At the time of this most recent open-label extension data analysis on functional assessments, all 13 boys continuing to participate had received 100 mg/kg/day for 48 weeks and 8 had reached 60 weeks of 100 mg/kg/day edasalonexent treatment.

Additional supportive measures of muscle health also reinforce positive edasalonexent treatment effects in the 100 mg/kg/day treatment group. Four muscle enzymes (creatine kinase, alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase) were significantly decreased compared to baseline following edasalonexent treatment at 12 weeks and later time points through 60 weeks (p<0.05), consistent with the ability to slow muscle degeneration and improve muscle integrity. Biomarker results showed that CRP was significantly decreased with edasalonexent at 12, 24, 36 and 48 weeks compared to baseline in the 100 mg/kg/day treatment group (p≤0.001). CRP is a well-characterized blood test marker that provides a global assessment of inflammation, and CRP is elevated in boys affected by DMD. The significant decrease observed in CRP supports the biological activity of NF-kB inhibition by edasalonexent treatment decreasing inflammation.

Edasalonexent continued to be well tolerated with no clinical safety signals observed to date. The majority of adverse events (AEs) have been mild in nature with no serious AEs. The most common related AEs were gastrointestinal, primarily mild and transient diarrhea. Boys with DMD in this age range typically have resting tachycardia, a heart rate that exceeds the normal resting rate, and the heart rate of the boys treated with edasalonexent decreased toward age-normative values during treatment.

Catabasis plans to initiate a single global Phase 3 trial in DMD in the first half of 2018 to evaluate the efficacy and safety of edasalonexent for registration purposes. The design of the randomized, double-blind, placebo-controlled trial has been informed by discussions with FDA and EMA. The Phase 3 trial is expected to have many key elements in common with the Phase 2 trial, including the patient population and functional endpoints. Catabasis anticipates enrolling approximately 125 patients between their 4^th and 7^th birthday who have not been on steroids for at least 6 months. Boys on a stable dose of eteplirsen may be eligible to enroll. The primary efficacy endpoint will be change in the North Star Ambulatory Assessment score after 12 months of treatment with edasalonexent compared to placebo. Key secondary endpoints are planned to include age-appropriate timed function tests. Assessments of growth, cardiac and bone health are also planned to be included. Catabasis expects to report top-line results from this trial in 2020.

About the MoveDMD Trial
The MoveDMD trial is investigating the safety and efficacy of edasalonexent in steroid-naïve boys enrolled at ages 4 – 7 affected with DMD (any confirmed mutation). The trial is comprised of three parts – Phase 1, Phase 2 and open-label extension. Phase 2 was a randomized, double-blind, placebo-controlled 12-week portion with 31 ambulatory boys across a range of dystrophin mutations. The 12-week MRI T2 primary endpoint for treated boys compared to placebo was directionally positive although not statistically significant. The open-label extension evaluated longer term safety and efficacy using pre-specified analyses comparing the rates of change in boys receiving edasalonexent treatment and prior to treatment. In the Phase 2 and open-label extension of the MoveDMD trial, edasalonexent substantially slowed DMD disease progression in boys on 100 mg/kg/day through 60 weeks of treatment. Across all assessments of muscle function, consistent improvements were observed in the rate of decline after 12, 24, 36, 48 and 60 weeks of oral 100 mg/kg/day edasalonexent treatment compared to the rate of change in the control period for boys prior to receiving edasalonexent treatment. Statistically significant improvements were also seen across available non-effort based measures of muscle health. In the 100 mg/kg/day treatment group, 16 boys commenced edasalonexent either at the beginning of Phase 2 or at the beginning of the open-label extension. Edasalonexent was well tolerated with no safety signals observed in the trial. Catabasis expects to present additional data at scientific meetings in 2018.

About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule that is being developed as a potential disease-modifying therapy for all patients affected by DMD, regardless of their underlying mutation. Edasalonexent inhibits NF-kB, a protein that is activated in DMD and drives inflammation and fibrosis, muscle degeneration and suppresses muscle regeneration. Edasalonexent continues to be dosed in the open-label extension of the MoveDMD Phase 2 clinical trial and Catabasis plans to initiate a single global Phase 3 trial to evaluate the efficacy and safety of edasalonexent for registration purposes in the first half of 2018. The FDA has granted orphan drug, fast track and rare pediatric disease designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. For a summary of clinical results reported to-date, please visit www.catabasis.com.

About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART Linker^SM platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company’s drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.

Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about future clinical trial plans including, among other things, statements about the Company’s plans to commence a single global Phase 3 trial in DMD in the first half of 2018 to evaluate the efficacy and safety of edasalonexent for registration purposes, the Company’s plans to report top-line results from this trial in 2020, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates, including the final trial design of the Company’s planned Phase 3 trial in DMD; availability and timing of results from preclinical studies and clinical trials, including the availability of top-line results from the Company’s planned Phase 3 trial in DMD in 2020; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; the Company’s ability to obtain financing on acceptable terms and in a timely manner to fund the Company’s planned Phase 3 trial of edasalonexent in DMD for registration purposes; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the Company’s product candidates; and general economic and market conditions and other factors discussed in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2017, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

$ZN Encounters Oil, Company Drills Deeper in Response

Zion Oil & Gas, Inc. (NASDAQ: ZN) announces that during the current open hole wireline logging and subsequent reaming (cleaning the well bore) operations, Zion encountered free-flowing hydrocarbons while circulating drilling mud.

Zion’s President and Chief Operations Officer, Dustin Guinn, provided further understanding of recent events stating, “We were cautiously optimistic given the amount of gas that accumulated in the well after returning from Shabbat after calling total depth (TD) at 5,026 meters (~16,500 feet).  After making our first of three open hole logging runs, we decided to ream to bottom to clean the hole out in anticipation of our second logging run.  After circulating the well, we experienced a continued and significant increase in gas followed by clear evidence of oil in our circulated mud from the bottom of the well.  This is obviously very exciting news and as a result, we have decided to continue to drill up to another 70 meters (~230 feet).  We expect that to take a couple of days, and barring any operational difficulties, we will continue with our open hole logs immediately thereafter.”

Zion’s CEO, Victor G. Carrillo, added, “I am ecstatic to see clear evidence of hydrocarbons (oil and gas) in the deeper portion of our Megiddo-Jezreel #1 well – a project that we have been working on for years. However, at this time we cannot comment on the commerciality or ability to successfully produce the well.  We ask that our shareholders continue to pray for safe and successful drilling, logging, and testing operations, and for God’s wisdom for management as we make key decisions in the following days and weeks. Please be patient. We will provide further updates after we have adequate time to properly evaluate the logs and finalize our well testing program following the recent events.”

“For You are great, and do wondrous things; You alone are God.” Psalm 86:10

“In His hand are the deep places of the earth …” Psalm 95:1-7

FORWARD-LOOKING STATEMENTS: Statements in this communication that are not historical fact, including statements regarding Zion’s planned operations, anticipated attributes of geological strata being drilled, the presence or recoverability of hydrocarbons, operational risks in testing and well completion, timing and potential results thereof and plans contingent thereon are forward-looking statements as defined in the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions that are subject to significant known and unknown risks, uncertainties and other unpredictable factors, many of which are described in Zion’s periodic reports filed with the SEC and are beyond Zion’s control. These risks could cause Zion’s actual performance to differ materially from the results predicted by these forward-looking statements. Zion can give no assurance that the expectations reflected in these statements will prove to be correct and assumes no responsibility to update these statements.

Contact Info:
Zion Oil & Gas, Inc. (NASDAQ: ZN)
12655 North Central Expressway, Suite 1000, Dallas, TX 75243
Andrew Summey
Telephone: 888-891-9466
Email: andrew.summey@zionoil.com
www.zionoil.com

$PVOTF Pivot Provides Market Activity Update

VANCOUVER, British Columbia, Feb. 13, 2018 — via NetworkWire – Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), a biopharmaceutical company engaged in the development and commercialization of cannabinoid-based therapeutics using innovative drug formulation and delivery platform technologies, wishes to to address the recent decline in its share price.

There has been no material change to Pivot’s business plan that would justify the market decline. Pivot continues to successfully execute on its business strategy. Product development is advancing as planned and discussions are ongoing with potential acquisition or joint venture partners. We continue to aim for product sales commencing with the change in regulations anticipated to take effect in Canada in July 2018. Our recent press release clearly highlighted several key milestones achieved by Pivot and its world-class scientific collaborators.

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to a Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.  PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

Cautionary Statement
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot or Pivot Green Stream, or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. As a result of the foregoing, actual results could differ materially from those contemplated by the forward-looking statements as a result of the foregoing factors and certain other factors, such as the failure to meet the conditions imposed by the regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact:
Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Info@PivotPharma.com

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$ETST Cannabinoids Lead to Marijuana Biotech Boom

February 13, 2018

NetworkNewsWire Editorial Coverage: As the legalization of medical marijuana spreads, the appetite for investment in the cannabis biotech sector keeps growing. This is the largest sector of the legal cannabis market, already a multi-billion-dollar market. Researchers continue to uncover new ways that cannabinoids, chemical compounds found in cannabis, can be used as medicine. Earth Science Tech (ETST) (ETST Profile) offers full-spectrum, high-grade hemp cannabidiol (CBD) oil, and is researching cutting-edge CBD products through its subsidiary Cannabis Therapeutics, Inc. (CTI). The creator of the first cannabis-based prescription medicine, GW Pharma (GWPH) is working on new drugs to tackle epilepsy, while Medical Marijuana, Inc. (MJNA) provides a range of CBD oils with medical and nutritional benefits to customers across North and South America. CV Science, Inc. (CVSI) utilizes separate drug development and consumer product divisions to create and market a diverse range of CBD products to a variety of markets, and Cannabis Science, Inc. (CBIS) is developing formulation-based drugs based on cannabinoid science.

A Thriving New Sector

The legal cannabis sector is booming. According to the Brightfield Group, it is already worth over $7 billion and expected to grow to $31 billion by 2021. Within that market, CBD products are a significant sector, expected to hit $1 billion in the next few years. Even the more conservative U.S. states are overcoming their objections and opening up to CBD production and sales, as legislators seek to resolve legal ambiguities in favor of patients.

While the emergence of a recreational cannabis market in regions such as Canada and California is exciting news for the cannabis industry, the industry’s financial security rests on medical products. The loosening of laws makes research easier, as does the growing experience of medical cannabis companies. CBD is a particularly rich source of therapeutics with the potential to be utilized against a wide range of ailments. Researchers are exploring its potential to tackle such enduring problems as epilepsy, anxiety, depression and breast cancer.

Innovating in Cannabidiol

Biotechnology company Earth Science Tech (ETST) has diverse interests within the cannabis market. Its subsidiaries cover diagnostics and vaccines, recreational cannabis and CBD products. In that last area, it’s leading the way in researching and marketing a wide variety of CBD-based treatments through innovative partnerships and collaborative research.

Earth Science Tech’s CBD work is carried out through its subsidiary Cannabis Therapeutics, Inc. (CTI). The company’s CBD oil is 100 percent natural and organic, catering to the environmental concerns common among cannabis users. It is made using a CO2 liquid extraction process that results in a full-spectrum, high-grade hemp CBD oil that has the highest purity and quality on the market.

To keep it in the lead of the CBD market, Earth Science Tech has created partnerships with other research bodies to produce cutting-edge treatments. It is working with the University of Central Oklahoma and DV Biologics Laboratory on research and development projects to enhance the healthcare benefits of its CBD oil. This has positioned the company to take a leadership role in the development of cannabinoid-based pharmaceutical and nutraceutical products. The company holds a provisional application patent for a CBD product for treating breast and ovarian cancers, taking CBD treatments in bold new directions.

Reaching New Market Sectors

Cannabis Therapeutics currently has two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products in development. These are being made to treat a range of ailments including anxiety, depression and fatty liver disease.

One major focus is integrating the CBD molecule with existing generic drug molecules to create more efficient medications that have fewer side effects than the more common approaches. The company is therefore engaged not only in making cannabinoids useful and available to a wider range of patients, but in creating a better experience for existing patients.

Other research into medical cannabinoids by Earth Science Tech could counter conservative fears about the impact of medical cannabis on the illegal drug market. In November 2017, the company began human trials on a new CBD formula designed to decrease cravings and the negative effects of withdrawal in opioid addicts. Based on industrial hemp CBD mixed with a natural ingredient that increases dopamine levels, it could be used to counter the opioid epidemic plaguing many countries. By turning medical CBD into a weapon in the fight against addiction, it will reposition cannabis in the public discourse on drug use. This has the potential to counter resistance to the expansion of the medical cannabis market.

Raising the Brand Profile

Earth Science Tech has a wide variety of products, giving it good reach within the CBD market. Its CBD treatments are available as vitamins, minerals, herbs, botanicals, personal care products, homeopathic treatments and foods. Other products come in forms including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Available at retail stores across the United States and online, they have a combination of physical shelf presence and online visibility to raise their profile with consumers.

The company is currently rebranding its CBD products (http://nnw.fm/s6pC1), using market research to drive improved sales. The chief marketing officer commented, “We did a lot of market research to see what the best angle to truly stand out in the growing CBD industry is through our accounts, representative feedback, and external brand analysis. I feel that marketing, ‘High Grade Full Spectrum Cannabinoids’ will help ETST truly stand out. Soon, the market will be able to see that ETST is a true full spectrum CBD brand, especially with the cannabinoid complex listing under the supplement facts.”

As a result of this research, previous marketing of the company’s products as, “High Grade Hemp CBD Oil” is being replaced with “High Grade Full Spectrum Cannabinoids.” Branding will also include the addition of “Cannabinoid Complex”. The supplement facts will show the breakdown of the full spectrum of CBD oils being used, including CBD, CBG and CBDA.

Box packaging has been designed to incorporate these changes and a modern, edgy look while maintaining the clean design associated with medicinal products.

Better Distribution

Taking these revamped products into American stores (http://nnw.fm/pd51A) is the first major distributor for Earth Science Tech’s products — Mr. Checkout.

Mr. Checkout, as featured on ABC’s Shark Tank, is a national group of independent distributors, full-line grocery distributors and convenience stores. It represents products in over 60 major U.S. retail outlets with approximately 55,000 stores. Mr. Checkout’s accounts include Walgreens, CVS, Walmart, Wholefoods Market and Target. This distribution deal provides a direct route for Earth Science Tech’s products onto the shelves of powerful retail stores with a large consumer base.

Earth Science Tech has 10 active representatives opening and managing accounts across the United States. These representatives have been very successful with health food stores and clinics. The distribution agreement with Mr. Checkout will take the company’s products beyond this market, into major retailers and stores, substantially expanding the company’s reach.

Gabriel Aviles, Earth Science Tech’s chief sales officer and director, said about the deal, “I feel that we have finally put together a solid productive team of representatives that we needed to continue expanding our presence in health shops and clinics. Now, with Mr. Checkout, we will be able to take our presence and sales to the next level, entering larger retailers and many stores. 2018 looks to be starting off very strong with our new product revamp, marketing and education strategy, and sales channel.”

Growing Consumer Choice

The growth of the medical cannabis sector means that Earth Science Tech’s products sit among a wide range of brands on the ever-growing shelves of CBD oils.

British cannabis company GW Pharma (GWPH) has developed Sativex, the first prescription medicine derived from the marijuana plant. This has been approved for Multiple Sclerosis spasticity and neuropathic pain in 29 countries. The company is currently seeking FDA approval for Epidiolex, a CBD-based treatment for epilepsy, after the drug was found to be effective in clinical trials.

Medical Marijuana (MJNA), one of the pioneers of the cannabis sector in North and South America, offers its flagship product Real Scientific Hemp Oil (RSHO) in three varieties. RSHO was the first legal CBD oil in both Brazil and Mexico, and the company was the first publicly traded cannabis business in the United States. A global leader in the medical marijuana industry, this forward-looking company is also exploring the nutritional potential of hemp.

CV Science (CVSI) is divided into two segments: a drug development division focused on creating and commercializing novel CBD-based therapeutics, and a consumer product division that manufactures, markets and sells plant-based CBD products. It is tapping into a wide range of market sectors through products such as its Purified Liquids products for vaping. Its PlusCBD Oil is the top-selling brand of hemp-derived CBD oil for consumers in the natural products industry.

Recognizing the long history of cannabinoids for health purposes and supporting peer-reviewed scientific journals, Cannabis Science (CBIS) is focused on the discovery and development of novel cannabinoid-based therapies as treatment options for unmet medical needs. Its immediate focus is on the treatment of cancer.

Cannabinoids are an increasingly important part of the growing cannabis sector. Companies that can combine strong branding, customer outreach and innovative products are likely to see great growth as the market expands by billions each year. And as research finds new therapeutic uses for these chemicals, they are set to improve the lives of thousands of patients.

For more information on Earth Science Tech, visit Earth Science Tech (ETST)

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

$DARE Enters License and Collab. Agreement for FDA First in Female Sexual Arousal Disorder

Company enters into license agreement with Strategic Science & Technologies, LLC to develop Topical Sildenafil, now in Phase 2 clinical studies

SAN DIEGO, Feb. 12, 2018  — Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced it has entered into an agreement to license SST-6007 (5% Topical Sildenafil Citrate Cream), a potential treatment for Female Sexual Arousal Disorder (“FSAD”), from Strategic Science & Technologies, LLC (“SST”). FSAD is characterized primarily by an inability to attain or maintain sufficient physical sexual arousal that causes distress or interpersonal difficulty.  SST-6007 incorporates sildenafil, the same active ingredient in Viagra®, in a proprietary cream formulation that is specifically designed to locally increase blood flow to the vulvar-vaginal tissue in women, leading to a potential improvement in genital arousal response and overall sexual experience. If approved, Daré believes SST-6007 would be the first FDA approved treatment for FSAD.

SST-6007 is the second product in Daré’s growing portfolio of novel therapeutic candidates that address unmet needs in women’s reproductive and sexual health. Daré’s first product candidate undergoing clinical development in the United States is Ovaprene™, a non-hormonal contraceptive ring with the potential to be the first non-hormonal product to provide monthly contraceptive protection.

“We look forward to working closely with SST to bring SST-6007 to the market for women, leveraging SST’s deep knowledge of FSAD and our experience developing innovative women’s health products and readying them for U.S. commercialization. Driven by a mission to identify unmet needs in women’s health and mining the globe for unique assets that would serve these needs, we are confident that SST-6007 has the potential to significantly impact women with Female Sexual Arousal Disorder, an area that has long been studied but for which there are currently no FDA approved treatments,” said Sabrina Martucci Johnson, President and CEO, Daré Bioscience.

“While increased attention has been focused on female sexual dysfunctions over the past several years, no pharmacologic options have yet been FDA approved for Female Sexual Arousal Disorder (FSAD), a condition which significantly compromises a woman’s ability to have a pleasurable sexual experience,” commented Dr. Sheryl Kingsberg, Division Chief, OB/GYN Behavioral Medicine, UH Cleveland Medical Center. “I am very excited about the potential for Topical Sildenafil to address this critical unmet need in women’s sexual health. Leveraging the known therapeutic benefit of Viagra® to stimulate increased blood flow to the genital tissue, Topical Sildenafil may offer these women a safe, effective and ‘on demand’ solution to difficulties with sexual arousal allowing for a more intense and enjoyable sexual experience.”

In a Phase 2 study, SST-6007 demonstrated an increase in blood flow to the vaginal tissue in both pre- and postmenopausal women with FSAD.  Daré plans to pursue the 505(b)(2) regulatory pathway for SST-6007 in the U.S. and leverage the existing data and established safety profile of the Viagra® brand.  Daré anticipates commencing a Phase 2b clinical trial in the second half of 2018.

With the potential introduction of SST-6007 as the first FDA approved product for FSAD, Daré is poised to create a new market category within the female sexual dysfunction space.  A report by Visiongain forecasts that the world market for both male and female sexual dysfunction drugs will reach $7.7 billion in 2019.

About Strategic Science & Technologies, LLC

Strategic Science & Technologies, LLC (SST) is a clinical-stage biotechnology company with an innovative topical drug delivery technology. The company’s patented delivery technology provides targeted local delivery of known drugs at therapeutic levels.  SST’s product portfolio includes Topical Ibuprofen and Topical Sildenafil, both in clinical development.  SST is headquartered in Cambridge, MA and remains privately funded by its original investors. For more information please visit www.strategicscience.com.

About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. The company is driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Daré’s lead product candidate, Ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies. The company is headquartered in San Diego. For more information please visit www.darebioscience.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995 regarding matters that are not historical facts, including statements relating to Daré’s expectations regarding the anticipated market demands for its products, the safety and effectiveness of its products, market acceptance of Daré’s products and the qualifications and expertise of Daré’s management team. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals; claims of infringement and other risks relating to Daré’s owned and licensed intellectual property rights, and other factors discussed in the “Risk Factors” section of Daré’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2017. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Daré’s reports to the Securities and Exchange Commission, including Daré’s reports on Forms 10-Q, 8-K and 10-K. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. Daré specifically disclaims any obligation to update any forward-looking statements included in this press release.

Media Contact:
Amanda Guisbond
Vice President
Canale Communications
Amanda@canalecomm.com
781-405-8775

$CIIX NetworkNewsAudio Audio Press Release on Hemp Opportunities in CBD Market

New York, New York–(February 12, 2018) – NetworkNewsAudio announces the Audio Press Release (APR) titled “Hemp Provides Investors Access to Larger Cannabidiol Market,” featuring ChineseInvestors.com (CIIX).

To hear the NetworkNewsAudio version, visit: LINK

To read the original editorial, visit: LINK

The company’s hemp-based health products are available in the United States and Canada. CEO Warren Wang aims to double the company’s revenue and expand the business in 2018, with growth in North America as well as China. One of the tools to achieve this is a Yelp-style app for CBD customers. Approved for download by the Apple App Store, it is the world’s first Chinese-language mobile cannabis navigation application. The app carries an easily searchable database of marijuana dispensaries and cannabis strains. Customers can use the platform to review and discuss cannabis products, allowing them to find the best recommendations and nearby locations for medical and recreational cannabis. This will broaden the company’s reach and raise its profile in the growing number of states where marijuana is legally accessible.

CIIX is committed to further research into the use of hemp oil and other CBD products. The company in investing in research and design enterprises with the goal of developing CBD drugs to combat epilepsy and Alzheimer’s disease. The application period for new drugs of this type in China is two to four years, meaning that the company will be able to bring products to market far more quickly than in the United States. If this research pays off, then the company will not only be providing new uses for products in a growth sector of the economy, it will also be in position to launch them in the largest customer market in the world.

About ChineseInvestors.com

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail and online sales of hemp-based products and other health related products. For more information visit www.ChineseInvestors.com.

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact: 
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$PVOTF Provides Corporate Update

VANCOUVER, British Columbia, Feb. 12, 2018  — Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), a biopharmaceutical company engaged in the development and commercialization of cannabinoid-based therapeutics using innovative drug formulation and delivery platform technologies, is pleased to provide its shareholders with the following Corporate Update.

Pivot has had a very active start to 2018 as the management team continues to build a “differentiated” company in the cannabis sector, focusing on improving the cannabis consumer experience with scientifically derived products. Pivot’s world-class patent portfolio and industry leading pipeline, supplemented by experienced scientists and developers, will allow the Company to flourish as it continues to produce effective, stable and dosable products for health-conscious consumers.

Current products available to consumers are either smoked or are unable to deliver meaningful amounts of cannabis into the body. Pivot believes that only companies that have pharmaceutical-grade products supported by strong clinical or medical data will meet the consistency and desired health effects demanded not only by consumers, but also by regulatory authorities such as Health Canada.

Highlights:

1. Acquisition of ERS Holdings, LLC (“ERS”) and Ready-to-Infuse-Cannabis Patents: Pivot has completed the Definitive Agreement and closing is scheduled on or before February 28, 2018. Monetization of the patented Ready-To-Infuse-Cannabis Oil-to-Powder technology (“RTIC”) is a top priority for Pivot. A recent report states that cannabis sales have surpassed liquor store sales in Aspen, Colorado for the first time since legal adult-use sales began in 2014. Forbes, citing a study by Cannabiz Consumer Group, states that “the beer industry could lose more than $2 billion in retail sales to legal marijuana”. With the ERS acquisition, Pivot is well positioned to participate in the lucrative global cannabis-infused-beverage market and has already identified potential co-development partners in the alcohol beverage industry.
2. Acquisition of Thrudermic, LLC: Pivot previously announced a Binding Letter of Intent to acquire worldwide rights to Thrudermic’s patented Transdermal Nanotechnology for the development and commercialization of transdermal cannabinoids. The Company has now exercised its right to acquire 100% of Thrudermic, LLC, with closing scheduled on or before February 28, 2018. Pivot’s management has been very impressed with the capabilities of Dr. Leonid Lurya and Dr. Joseph Borovsky and are excited to have them lead Pivot’s product development team. The ability to develop products in Israel using Dr. Lurya’s patents provides the Company with access to CBD/THC licensed labs, ensuring that Pivot will have several products ready for sale in countries where regulations permit.
3. Product Development Update:a. Micelle 1% CBD oral solution is ready for market. Formulated using Solmic GmbH’s patented solubilisation technology, CBD is rendered water-soluble and results in higher bioavailability and stability.
   b. Pivot Topical CBD: Dr. Leonid Lurya, working in partnership with Solubest Ltd. (located in the Weizmann Science Park in Israel) has now completed formulation of this product. The semi-solid cream is being evaluated for stability at this time.
   c. Pivot’s development team has initiated development of Thrudermic transdermal nanotechnology for a systemic CBD product.
4. Growing IP Portfolio: Pivot continues to evaluate drug delivery technologies that can assist with the delivery of cannabinoids for human and veterinary use. The Company has filed three additional provisional patents for using nanotechnology delivery of cannabis from various routes of administration:a. Transdermal nanotechnology delivery system of cannabis using patches and creams;
   b. Mucus topical cannabis delivery system through buccal, nasal, vaginal and anal areas of entry using a gel, suppository or mouthwash; and
   c. Inhalation delivery system of cannabis for topical or systemic use.

   In addition, the Company is expecting positive feedback from the United States Patent and Trademark Office regarding continuation patents using RTIC technology which will allow for novel formulations of cannabis with various health and wellness products such as over-the-counter sleep aids, and cough and cold medication among others.  This is in addition to capsules, K-Cups, stick packs, and other infused beverages such as vitality drinks.

5. Standstill Agreement: The previously announced Standstill Agreement has been mutually terminated and as a consequence, other broader opportunities have arisen. Pivot will favor those options that allow it to control all aspects of the cannabis process, from raw materials to formulation, resulting in the highest quality bio cannabis products. These options may include the acquisition of, or Joint Venture with, a Licensed Producer and/or Licensed Dealer. Pivot’s management will select the transaction that helps create a long-term, sustainable company and provides the greatest value for shareholders.
6. Out-licensing of Pivot’s IP: Pivot continues to receive inquiries from companies interested in licensing pipeline products and/or patents. This interest confirms the validity of Pivot’s IP strategy. As the cannabis space is emerging, only those products with adequate IP protection will provide a competitive advantage, allow trademarking and branding, and protect innovation.
7. European Distribution Partner: Pivot has selected and advanced discussions with an established European-based natural health company to market and distribute products in the EU. A report by Prohibition Partners mentions that “the European medical cannabis market will be valued at almost €50b once all markets have implemented legislation and market infrastructure. This does not include revenue that will be generated from the additional secondary market and ancillary services. EIHA, Nova-Institute and HempConsult estimate that the European market for CBD as a pharmaceutical product is already worth €2b alone.”

Dr. Patrick Frankham, Pivot’s CEO states “I am extremely proud of the entire Pivot team as we continue to execute our business plan. We are overwhelmed by interested companies who now understand that derivatives and superior formulations will improve cannabis product experience and healthy outcomes.  We continue to believe that sustainable cannabis companies will have pipelines of products to meet the needs of consumers seeking wellness and healthy lifestyles.”

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to a Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.  PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

Cautionary Statement
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot or Pivot Green Stream, or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. As a result of the foregoing, actual results could differ materially from those contemplated by the forward-looking statements as a result of the foregoing factors and certain other factors, such as the failure to meet the conditions imposed by the regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact:
Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Info@PivotPharma.com

$IGC CEO to Speak at CEO Healthcare Symposium in NY on February 12-13

BETHESDA, Md., Feb. 12, 2018

India Globalization Capital, Inc. (NYSE-MKT:IGC) announced today that Ram Mukunda will be a speaker at the upcoming CEO Healthcare Symposium in New York on February 12 and February 13, 2018.  His presentation will include commentary on the Company’s efforts in developing and commercializing cannabis–based pharmaceuticals including Hyalolex for Alzheimer’s disease.

2018 Key Objectives

“We are preparing the groundwork necessary to prepare Hyalolex, our lead product formulation for Alzheimer’s ready for Phase 2-B human trials. Independent of this, we expect to make the product available through medical dispensaries in select states of the U.S. In addition, we are working on addressing issues specific to the medical cannabis industry such as transactional difficulties, inadequate product labeling, product identification assurance (PIA) and product origin assurance (POA), using distributed ledgers inherent in blockchain technology.  We look forward to an exciting 2018 and I wish to thank YJP for the opportunity to speak at their CEO Healthcare Symposium alongside prestigious leaders and innovators in the healthcare industry,” commented Ram Mukunda, CEO.

About the CEO Healthcare Symposium
This event, sponsored by YJP (www.yjp.org) will feature speakers from the hospital, insurance, biotech, pharma, medical device, medtech, senior living, and home care sectors and will bring together top executives from across the healthcare spectrum to discuss the current and future market trends that we are seeing in the industry.

About Alzheimer’s disease
Alzheimer’s Disease (AD) is a form of dementia.  It is known as America’s most expensive disease, with an estimated cost to the U.S. economy of $236 billion.  AD currently affects more than 5.3 million Americans and over 65% of AD patients are women.  Over the next 20 years, the number of those afflicted with the disease is expected to double.  The forecast is staggering, considering that to date, no effective cure has been found.

About IGC
IGC has two lines of business, a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry that address transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA).  The company is based in Maryland, USA.

For more information please visit www.igcpharma.com
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact:
Claudia Grimaldi
301-983-0998

$STLHF Exploring Lithium Extraction Potential of Arkansas Brine, NetworkNewsBreaks

January 30, 2018

• Standard Lithium works to reduce political, permitting and technology risks
• Standard Lithium is expanding facilities into southern Arkansas
• Innovative low-risk opportunities being sought to meet the increasing demand for lithium

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) actively seeks to reduce political, permitting and technology risks, all while positioning itself as a leader in the production of lithium. The company works to eliminate exploration and development risks by focusing on existing brine fields and partnering with U.S. chemical processing companies. By focusing on U.S.-based assets, Standard reduces political and geographical risks, working within jurisdictions that already understand how to permit and approve brine extraction and processing at large industrial scales. Whenever possible, Standard partners with companies holding existing permits and licenses in favorable jurisdictions. Technology risks are decreased by leveraging existing industrial processes and extraction technologies, partnering with world class chemical processing engineers and using leading scientific and engineering advisory teams.

A network of brine production wells in southern Arkansas provides access to the Smackover Formation. In a statement made by Standard Lithium’s Chief Executive Officer, Robert Mintak, there is talk of building a Pilot Plant “fed by a network of brine production wells in southern Arkansas that access underground brine from the Smackover Formation and transport it via an extensive system of pipelines and related infrastructure.”

In the last 80 years, the Smackover Formation has produced billions of barrels of brines. This opportunity will give the company access to tail brines for the testing of viable lithium extraction and aligns fully with Standard Lithium’s goal of creating efficient processing techniques to produce battery-grade lithium products from otherwise overlooked brine resources.

With the demand for lithium set to increase by more than 300 percent in the next eight years, the company is looking for innovative low-risk opportunities to meet the need. In the Mojave Desert of California, it is using the region’s record-high evaporation rates to its advantage. Standard has installed six new separate evaporation ponds at its Bristol Dry Lake property for extensive brine extraction and processing. The company’s project area in California covers over 45,000 acres, and its recent entry into an option agreement with TETRA Technologies Inc. will provide access to 33,000 acres of brine leases in southern Arkansas.

The world’s demand for lithium is on the uptick with the ever-increasing interest in electric vehicles, smartphones, laptops and other battery-operated technologies. Standard Lithium is positioning itself to be a leader in the industry. In 2017, its stock returned 348 percent to investors, and the company has a current market cap of around C$136 million.

For more information, visit the company’s website at www.StandardLithium.com

More from NetworkNewsWire

• Teewinot Life Sciences Corporation is Producing Cannabinoids without Touching the Plant
• Tapinator, Inc. (TAPM) Blazing Trails in Blockchain-Based Gaming App Development
• Reign Sapphire Corp. (RGNP) is “One to Watch”

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$PBIO WallStreet Research Announces Updated Corporate Profile Coverage

NEW YORK, NY / February 9, 2018 / WallStreet Research™ (WSR), a top-ranked independent research firm with a history spanning over three decades, today announced that the firm has updated corporate profile coverage on Pressure BioSciences, Inc. (OTCQB: PBIO). WallStreet Research™ is ranked Number One on the Google, Yahoo, and Bing search engines in both small and microcap research with a global following. An updated analyst Corporate Profile Report, together with additional information about WallStreet Research™, is available at the www.WallStreetResearch.org website.

The updated WSR Corporate Profile highlights the last half of 2017 accomplishments and the growth plans, which the Company (PBI) has implemented for 2018 and beyond.

One of the major accomplishments last year was the redesign and enhancement of their products and technology. Additionally, PBI has significantly expanded their sales and marketing capabilities. Earlier in 2017, PBI operated with just two domestic sales directors, yet it was still able to grow the company on such limited staffing. Recently, PBI has hired four more domestic sales directors, now operating with six sales positions, which should enable it to grow significantly in 2018. PBIO also has increased its distribution network by expanding the marketable territories for I&L Biosystems, exclusive agent for Western Europe. And adding Vita, Inc as exclusive distributor in Japan. The company already works with Powertech, exclusive agent for China.

PBI recently completed the acquisition of all assets of BaroFold, Inc. Among the assets acquired were all patents, equipment, and intellectual property relating to BaroFold’s PreEMT™ high-pressure protein refolding and disaggregation technology. This patented technology employs high pressure for refolding of recombinant proteins into their native structures for desired pharmacological activity. With the Company’s proven ability to develop and commercialize effective high-pressure technology solutions and grow its worldwide customer base, and with its recent expansion of its sales force, PBIO should increase the reach of BaroFold’s technologies into many new research laboratories and biopharmaceutical companies, increasing sales. PBI also has increased its efforts working with distributors to market its products now in the USA, China, Europe and the Pacific Rim.

2017 was a continued growth year for PBI. The Company reported that total revenue increased 20.7% to $646,061 for Q3 2017 as compared to $535,334 for Q3 2016. Third quarter 2017 products and services revenue increased by 21%, consumable sales increased by 158% and grant revenue increased by 23%. For the 9 months ended Sept 30, PBI reported total revenue growth of 11.6% to $1.74 million, and posted an operating loss of $3.3 million.

Mr. Alan Stone, Managing Director of WallStreet Research™, added, “WSR has followed Pressure BioSciences for some time now and the team is impressed with the Company’s continued ability to increase sales to record levels each quarter, cut costs, and position itself for long term growth. With the addition of more sales, together with plans in place for strengthening the balance sheet, we believe the Company is well positioned for significant growth during the upcoming quarters of 2018 and beyond. Additionally, we believe that the core value of the Company’s products and technologies are not being adequately valued in the marketplace.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Information on PBIO can be found at www.pressurebiosciences.com.

About WallStreet Research™

WallStreet Research™ (“WSR”) is a prominent research boutique led by Mr. Alan Stone, Managing Director of Alan Stone & Company, LLC (ASC). The firm specializes in the microcap and small cap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength, and outstanding long-term earnings growth possibilities. Mr. Stone was formerly a securities analyst and assistant portfolio manager at Merrill Lynch Asset Management, an investment analyst at Prudential Financial’s Capital Markets Group, and an investment banker with Ladenburg Thalmann & Company. The firm has offices in Los Angeles, CA, Palm Beach, FL, and New York City, NY, and is well known for discovering undervalued companies and bringing them to the attention of the investment community. ASC/WSR also arranges road shows for its publicly traded clients, before the investment community in New York City, California and Florida. Information on WallStreet Research™ can be found at www.WallStreetResearch.org.

Disclaimer

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to he accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investments in securities mentioned here contain inherent and significant risks, and are suitable only for speculative oriented investors. Any investments should only be made after consulting an investment professional. The featured company will pay a fee of $3,500 in cash to Alan Stone & Company LLC for preparation and distribution of this profile, including other potential fees associated with various consulting and investor relations’ services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.

Contact / Source:

WallStreet Research™

Alan Stone, 310-444-3940
astone@alanstone.com

Barbara Blake, 415-419-4239
bjblake1229@att.net

www.WallStreetResearch.org
www.SouthFloridaInvestmentForum.com
www.SouthernCaliforniaInvestmentForum.com
www.SmallCapConference.org

Pressure BioSciences, Inc.

Richard T. Schumacher, CEO
14 Norfolk Ave. South Easton MA, 02375
Phone: 508-230-1828
www.pressurebiosciences.com

$PVOTF Working on Smokeless Cannabinoid Delivery Options, CannabisNewsBreaks

February 1, 2018

• Transdermal cannabis-based therapy promises greater absorption, less side effects
• Global medical marijuana market projected to reach $55.8 billion U.S. by 2025
• Novel CBD delivery method targets array of unmet healthcare needs

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot’s recent acquisition of BiPhasix ™ Transdermal Drug Delivery technology for the delivery of cannabinoids (CBD) to patients provides the answer for an age-old problem associated with cannabinoid-based therapies: the lack of a robust smoke-less delivery mechanism.

Research into the bioavailability of cannabinoid-based therapeutics shows that rates of absorption vary greatly between smoking cannabis to an orally-consumed product, with a difference noted even between individuals. Cannabinoids are degraded in the stomach and smoking may not appeal to patients for health or lifestyle reasons. Topical delivery, while a better alternative, has suffered from weak formulation issues. Transdermal cannabinoid delivery, on the other hand, could provide a better alternative route since it reduces side effects and bypasses other absorption issues. In addition, transdermal delivery provides the benefit of enabling patients to access a steady stream of medication over a prolonged period with fewer side effects.

Pivot Pharmaceutical’s newly created subsidiary, Pivot Green Stream Health Solutions Inc. (“Pivot Green Stream”), will focus on improving the bioavailability of cannabinoid-based and pharmaceuticals. BiPhasix™ has been tested in FDA and EMA approved human clinical trials, which have shown the delivery system enhances the bioavailability of many drugs and improves clinical outcomes. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids (CBD) that can receive a Health Canada Natural Health Product (NHP) designation. This marketing method ensures a shorter development cycle and faster revenue generation opportunities.

Pivot Pharmaceuticals Inc., which has positioned itself as a growing and crucial vertical in the cannabis industry, represents a compelling opportunity in the biotechnology field. The company’s plans include working with Licensed Producers (LP) and Licensed Dealers (LD) to bring newer therapies to patients. The company has also applied to list on the Canadian Stock Exchange (CSE).

The global medical marijuana market is expected to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing number of states and countries gaining approval for using cannabis in therapeutic applications is expected to continue driving the market forward.

Pivot Pharmaceuticals has assembled a highly experienced management team, bringing together a wealth of clinical, commercial, product development and financial experience. Among the many healthcare targets in Pivot’s pipeline are cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology and eye disease.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

• Teewinot Life Sciences Corporation is Producing Cannabinoids without Touching the Plant
• Opportunity Amid Cannabis Banking Hurdles
• Earth Science Tech, Inc. (ETST) Eyes Uplisting to OTCQB, Retains Counsel for Planned Regulation A+ Tier 2 Financing

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$CIIX NetworkNewsWire Publication on HEMP Opportunities in CBD Space

February 8, 2018

NetworkNewsWire Editorial Coverage: With the rapid growth of the legal American cannabis market, other cannabidiol (CBD)-based products are often overlooked. In particular, hemp has the opportunity to reach medical and nutritional customers that cannabis can’t, and ChineseInvestors.com (CIIX) (CIIX Profile) is tapping into that market. With the potential to provide similar benefits without the same restrictions, hemp products can be sold in markets such as China, where cannabis remains illegal. It’s a part of the market that CBD industry leaders such as Freedom Leaf, Inc. (FRLF) are also catering to, with marketing and media products for hemp companies. Medical Marijuana, Inc. (MJNA), America’s first publicly traded cannabis company, is carrying its CBD business beyond the United States and across the Americas, while CV Sciences, Inc. (CVSI) combines scientific research with a consumer products division to bring innovative CBD products to the market. At the farming end of the supply chain, Terra Tech Corp. (TRTC) provides advanced agricultural solutions and new, better strains of cannabis for a growing market.

The Growing Cannabidiol Market

The market for legal marijuana is growing at an ever-accelerating rate. Recent research by Arcview Market Research and BDS Analytics indicates that sales in North America reached almost $10 billion in 2017 and are expected to reach $24.5 billion by 2021 as more markets are created for both medical and recreational use. But this is still a sector threatened by great uncertainties and limitations. With no legal cannabis market in many parts of the globe, and with the current U.S. administration dominated by anti-marijuana conservatives, legal marijuana represents the troubled part of a larger CBD market.

For companies looking to that wider market, hemp offers a growing option for the CBD industry, one unfettered by many of the restrictions limiting marijuana. A report by the Brightfield Group shows that hemp is likely to become a billion-dollar market in the next three years. Used like cannabis in medicinal and nutritional products, it benefits from a high portion of online purchases – nearly two-thirds of hemp sales happen online.

Hemp also has the potential to reach larger international markets. The American-led war on drugs has encouraged an international climate that’s hostile to cannabis sales, but in which hemp products mostly remain legal.

Bringing Cannabidiol Products to China

One of the companies best set to make the most of this opportunity is ChineseInvestors (CIIX).

Founded in 1999, ChineseInvestors.com is a leading financial information website for Chinese-speaking investors in both the United States and China. Through its website, the company offers a range of investor information and services, including real-time market commentary, analysis and educational products. It also provides support services for companies looking to get into the Chinese market, including consulting for companies considering going public, advertising services and public relations-related support. With information in both English and Chinese language character sets, it provides an accessible presentation for investors looking at China both from the inside and the outside.

This is built around the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. In this way, CIIX helps investors make informed investment decisions and helps them meet their individualized financial goals. This includes a division committed to cryptocurrencies (http://nnw.fm/3pwZV), producing daily videos to inform Chinese investors about this ever-growing and unregulated sector of the Chinese economy.

Its position at the intersection of American and Chinese markets has put CIIX in a perfect position to explore the wider cannabidiol market. Marijuana use is illegal in China, but CBD oils, including hemp-based CBDs, are legal. CIIX is committed to developing and distributing hemp-based products in hopes of helping people improve their overall health, targeting epilepsy, Alzheimer’s disease, cirrhosis of the liver and various other health conditions. With nearly 10 million epilepsy patients in China, products that can help these customers have the potential to become big sellers in a growing market.

In December 2016, CIIX reached a wholesale agreement with a CBD health brand. Off the back of this, it launched its new subsidiary ChineseCBDoil.com. This website went live on Jan. 31, 2017, providing the world’s first Chinese language online store for CBD health products. It provides a variety of nutritional supplements containing CBD, including soft gels, capsules and concentrates available to Chinese-speaking customers worldwide.

Though the company has emphasized the health benefits of CBD products, it is also leveraging its financial and marketing expertise to sell hemp-infused skin care products in China.

Sales thus far have been so successful that the company is spinning off its subsidiary — CBD Biotechnology and ChineseHempOil.com, Inc. — with the intention of listing the new company’s common stock on the OTCQB (http://nnw.fm/Mxi3e). The site offers a variety of hemp oil products, including OptHemp Ultra Premium oil, peppermint-flavored hemp oil in softgels and gummies, and the Gold Plus line of premium hemp oil.

CIIX CEO Warren Wang expressed his confidence in this new development, stating in a press release, “We are excited to announce our intention to spin off CBD Biotechnology and ChineseHempOil.com, Inc. as we believe the existing business lines and the new acquisitions in China, secured by CEO Summer Yun, will allow these entities to continue to grow in their respective markets, while bringing new value to the Company’s existing shareholders.”

Growth and Challenges in America

The company’s hemp-based health products are available in the United States and Canada. Wang aims to double the company’s revenue and expand the business in 2018, with growth in North America as well as China. One of the tools to achieve this is a Yelp-style app for CBD customers. Approved for download by the Apple App Store, it is the world’s first Chinese-language mobile cannabis navigation application. The app carries an easily searchable database of marijuana dispensaries and cannabis strains. Customers can use the platform to review and discuss cannabis products, allowing them to find the best recommendations and nearby locations for medical and recreational cannabis. This will broaden the company’s reach and raise its profile in the growing number of states where marijuana is legally accessible.

CIIX is committed to further research into the use of hemp oil and other CBD products. The company in investing in research and design enterprises with the goal of developing CBD drugs to combat epilepsy and Alzheimer’s disease. The application period for new drugs of this type in China is two to four years, meaning that the company will be able to bring products to market far more quickly than in the United States. If this research pays off, then the company will not only be providing new uses for products in a growth sector of the economy, it will also be in position to launch them in the largest customer market in the world.

Because CBD remains classified as a Schedule 1 drug under the Controlled Substance Act administered in the United States by the Drug Enforcement Administration, hemp sales are regarded as illegal by the federal government despite the growing number of states legalizing it under their authority. Schedule 1 drugs are identified as substances with a high potential for abuse, no currently accepted medical use in the United States and a lack of safety protocols under medical supervision (http://nnw.fm/Nm4CO). This prohibition is being challenged in court, and that challenge now has the backing of a cross-party group of Congress members. The Congressional group’s arguments to the court state that the DEA’s ruling on CBD was an “abuse of DEA’s administrative procedure and rulemaking authority” and contrary to the definition of hemp set down by legislators in the 2014 Farm Bill (http://nnw.fm/Y2EPp). With such strong political support, the hemp industry is optimistic that this case will result in clarity and a lifting of the restrictions to permit easier expansion of CBD-based sales for companies such as CIIX.

The Cannabis Industry Connection

The deep connection between hemp production and the wider cannabis industry is shown by the work of companies such as Freedom Leaf (FRLF). A leading media producer and distributor in the cannabis and hemp industries, Freedom Leaf is a trusted source of information in the sector. The company is involved in mergers and acquisitions in the marijuana industry and has a portfolio of news, print and digital multi-media verticals, websites and web advertising, establishing it as a media outlet and discussion forum for a growing group of industries. It also provides services in branding, licensing and marketing these products, positioning it to make the most of fast growth in this sector.

One of the great pioneers of the cannabis sector in both North and South America, Medical Marijuana, Inc. (MJNA) is also involved in hemp. The first publicly traded cannabis company in the United States, the company also is situated in Brazil and Puerto Rico. This forward-looking company is exploring the medical and nutritional potential of hemp.

CV Sciences (CVSI) is both a researcher into CBD-based medicines and a producer of consumer food products based on that research. It is tapping into a wide range of market sectors through products such as its Purified Liquids products for vaping. Its PlusCBD Oil is the top-selling brand of hemp-derived CBD oil for consumers in the natural products industry.

On the agricultural side, Terra Tech (TRTC) is a vertically integrated, cannabis-focused company committed to cultivating and providing the highest quality medical cannabis. Its research-led approach to cultivating and cross-breeding marijuana strains leads to better products for treating a wide range of ailments. Its greenhouse and hydroponic systems allow the safe, efficient growth of cannabis and other plants in urban farming facilities, expanding the options for production in the CBD industry.

With the wider CBD industry growing, companies such as ChineseInvestors.com are aiming to profit from the growing power of hemp and its legal position in a disputed market.

For more information on ChineseInvestors.com, visit: ChineseInvestors.com (CIIX)

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

$CIIX Hemp Provides Investors Access to Larger Cannabidiol Market

$IGC CEO on Uptick Newswire’s “Stock Day,” CFN Media Looks at Hyalolex in Alzheimer’s

PHOENIX, Feb. 08, 2018 — India Globalization Capital, Inc. (NYSE American:IGC) (the “Company”) provides IGC operations update on Stock Day Podcast with Everett Jolly.

IGC has a legacy business in infrastructure focused primarily in India, Malaysia and Hong Kong.  More recently the company has expanded into the Cannabis Pharmacy business, which will reach the United States and Canada.

“The diversification in IGC both geographically and by industry makes it an interesting investment,” said Jolly.  “The cannabis industry is rapidly growing in the United States; the Company’s decision to direct their attention to one specific area of study, Alzheimer’s, will allow parallel penetration into the industry.”

Mukunda commented, “We are preparing to release our first product, Hyalolex, through dispensaries in the next several weeks.  In parallel we are also pursuing a traditional FDA path that is in its pre-clinical phase.  Our product is the result of many years of research and I look forward to the positive effects it will have on Alzheimer’s patients.”

To view the interview in its entirety, click here: https://upticknewswire.com/featured-interview-ceo-ram-mukunda-of-india-globalization-capital-inc-nasdaq-igc/

About IGC

IGC has two lines of business, a legacy infrastructure and commodity trading business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry including transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA).  The Company is based in Maryland, USA.

For more information please visit www.igcpharma.com
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick.

Follow us and keep an eye on Uptick’s YouTube, Twitter, and Facebook​ for additional radio and video shows produced by Uptick! ​https://www.youtube.com/watch?v=kU5SVLp4org

Investors Hangout is a proud sponsor of Stock Day and Uptick Newswire encourages listeners to visit India Globalization Capital’s message board on: https://investorshangout.com/India-Globalization-Capital-Inc-IGC-56759/

Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact:
Claudia Grimaldi
301-983-0998

–ALSO TODAY–

Seattle, WA, Feb. 08, 2018 — CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering India Globalization Capital Inc’s (NYSE American: IGC) Hyalolex, a cannabinoid-based therapy that appears to act on many different hypotheses of disease modalities. Investors interested in the AD space may want to take a closer look at the stock.

Alzheimer’s disease has already become the sixth leading cause of death in the United States and could cost the healthcare system upwards of $1 trillion by 2050. While pharmaceutical companies have spent billions of dollars trying to cure the disease, experts still aren’t sure exactly what causes the condition and how to go about treating it. The good news is that there are some therapeutics that act on multiple potential underlying causes.

Elusive Alzheimer’s Treatments

Alzheimer’s disease affects over five million people in the United States and has become the sixth leading cause of death. Last year, the disease and related dementias cost the country $260 billion and is projected to cost about $1.1 trillion by 2050. It is America’s most expensive disease. About 10% of people over 65 are diagnosed with Alzheimer’s, and almost 66% of Alzheimer’s patients are women. At the same time, 35% of caregivers report that their health has gotten worse due to their care responsibilities, adding even further to the costs associated with the disease.

While there are several drugs that treat Alzheimer’s disease, the quest to cure the illness has frustrated even the largest pharmaceutical companies. The consensus for the past 25 years has been that the disease is caused by the build-up of a sticky plaque called beta amyloid in the brain. Billions of dollars were subsequently spent developing drugs to clear beta amyloid, but all of them have failed at various stages of clinical trials.

Some companies are shifting their focus to tau proteins, which get twisted and block the internal transport system of neurons. While one clinical trial focused on these proteins failed, the research remains in the early stages of clinical trials. Other researchers believe that over-reactive oxygen molecules are causing oxidative stress, which could lead to the build-up of beta amyloid plaque and other “symptoms” of the disease.

How Cannabis Could Help

India Globalization Capital’s Hyalolex (IGC-AD1) has been shown to act on many of these different pathways in early research studies. In addition to modulating beta amyloid production and inhibiting aggregation, the compound appears to inhibit hyperphosphorylation of tau proteins, enhance mitochondrial function, and modulate several endpoints of AD. The compound is also non-toxic to neurons and doesn’t product a “high” feeling.

Using an immunoblotting technique, Dr. Chuanhai Cao demonstrated that IGC-AD1 inhibits beta amyloid aggregation in a dose-dependent manner by increasing monomer levels. This addresses the “amyloid hypothesis” that states that the aggregation of amyloids into toxic oligomers is a key pathogenic event in the onset of AD. These plaques could also trigger other pathological events, such as oxidative damage and inflammation.

The same technique of using immunoblotting showed that IGC-AD1 reduced the expression of an enzyme that enables phosphorylation by as much as 53% to 62%, which reverses some of the pathological effects of overexpressed APP and tau proteins. This addresses the “tau protein hypothesis” that states that tau protein phosphorylation is three to four times higher than a normal brain, which could be the underlying cause of AD.

Finally, Dr. Cao showed that IGC-AD1 enhanced mitochondrial function by between 30% and 60%, which could address the “mitochondrial cascade hypothesis”. This hypothesis is based on the notion that mitochondrial dysfunction – which worsens with age naturally – could start a cascade that ultimately leads to the disease. Evidence has also shown that elevated beta amyloid levels contribute to these mitochondrial abnormalities.

Other than the evidence showing that Hyalolex may address the three disease etiological hypothesis as outlined above, Hyalolex at larger doses may reduce patient anxiety, patient aggression, sleep disorder and alleviate overall caregiver distress.

Commercialization Strategy

Hyalolex is a liquid formulation that comprises of cannabis extracts, including THC, along with other natural compounds. It will be prescribed in two different doses. The smaller dose for mild to moderate AD patients, and the larger dose for moderate to advanced patients. IGC plans to distribute its technology through licensed medical cannabis dispensaries in the United States. This process will include state-by-state sourcing, formula assembly, packaging, and distribution utilizing best practices to ensure quality control while complying with the current legal guidelines established by each individual state.

Management plans to begin the rollout in the first half of this year in Washington D.C., Maryland, and California dispensaries. To help facilitate the rollout, the company engaged The Medical Marketing Group inc., a provider of outsourced product-detailing, education, and outreach services. The company projects the rollout of Hyalolex in 10 of the 29 legal states in 2018.

In addition to its launch across dispensaries, the company is preparing the groundwork necessary for Phase 2B human trials with the U.S. Food and Drug Administration (FDA). The company’s most recent results showed compelling in vivo data from genetically engineered mice, including marked 50% improvement in spatial memory. If these results translate to humans, the drug program could be groundbreaking within the industry.

Please follow the link to read the full article:

http://www.cannabisfn.com/india-globalizations-hyalolex-shows-promise-treating-patients-alzheimers-disease/

For more information, visit the company’s website at http://www.igcinc.us/.

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:http://www.cannabisfn.com

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Contact: 
CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com

$ETST Launch Date & Forecasts for Revamped Industrial Hemp CBD Products

Doral, FL, Feb. 08, 2018 — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabinoid (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announced launch date for the Company’s highly-anticipated, revamped industrial hemp Cannabidiol (CBD) products, which lead to forecast updates reflecting to a record-high monthly revenue.

February 13, 2018 is the official launch date for the Company’s highly anticipated High Grade Full Spectrum Cannabinoids product, and corresponding marketing strategy, announced early December 2017.

High Grade Full Spectrum Cannabinoids is composed of European CO2, supercritical extracted, organically grown, and unfiltered industrial hemp. The Company was originally planning on using American industrial hemp but was able to secure a reliable high-quality source in Europe to continue offering European industrial hemp, which led to slight delays from the original launch time frame. ETST will be one of the first companies to market its industrial hemp product as a Cannabinoid Complex instead of CBD, disclosing the milligrams (mg) of each Cannabinoid (CBD, CBDV, CBG, CBC, CBN, & CBDA). Cannabinoid complex is naturally occurring in the industrial hemp plant used, and is rich in Terpenes, and Saponins. Mixed, bottled, and packaged in the U.S. at a CGMP facility, the Company’s High Grade Full Spectrum Cannabinoids offer the highest therapeutic quality that current end-users trust and carry forward. Preorders are currently being accepted online.

Since last year’s announcement on product and marketing strategy revamp, Mr. Checkout distributor launched last week, and new veteran Chef Sales Officer, (CSO), the exponential demand increase has led the Company to revise forecasts to reflect what is anticipated to be the highest revenue month to date. The Company has new chain stores, clinics, and health shops eagerly waiting for the official launch to place their initial orders.

Nickolas S. Tabraue, ETST’s president, director and COO concludes, “Between appointing a new Chief Sales Officer, launching revamped industrial hemp products with fresh branding and marketing strategies, and our new distributor Mr. Checkout, we are on track for a record-setting revenue month. We’ve made clear that we intend to make 2018 our breakout year, and we are laying a strong foundation in this first quarter. We will continue to provide updates on our material events as we can.”

“While much of the up-listing and Reg A+ offering processes are out of our hands, we want to reassure our shareholders that we have worked hard to prepare the required paperwork for our audit and offering filings. We are prioritizing transparency and creating lasting value for our stakeholders and are committed to up-listing to the QB tier of the OTC Markets this year. We will provide updates as progress is made.”

About Earth Science Tech, Inc. (ETST): Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil.

To learn more and to buy CBD Hemp Oil, please visit: www.EarthScienceTech.com

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases). Earth Science Pharmaceutical CEO Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.EarthSciencePharmaceutical.com

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals, as well as other products & solutions. Cannabis Therapeutics’ mission it to help change the health care landscape by introducing its proprietary cannabis-cannabinoid-based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.CannabisThera.com

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.KannaBidioiDInc.com

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Dave Demarest (305) 546-7640

Earth Science Tech, Inc. Nickolas S. Tabraue, P/D/COO (305) 615-2118

$PVOTF Engages NetworkNewsWire for Corporate Communications Solutions

NEW YORK, Feb. 08, 2018 — via NetworkWire – Pivot Pharmaceuticals Inc. (OTCQB:PVOTF), an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies, announces that it has engaged the corporate communications expertise of NetworkNewsWire (“NNW”).

“Pivot’s key competitive advantages include cannabis formulation and delivery technologies, scientific and regulatory expertise, product sales and distribution experience, and our ability to work with best-in-class global partners,” Pivot CEO Dr. Patrick Frankham said. “We continue to create shareholder value by building a sustainable, long-term company that is well positioned in the fast-changing cannabis industry.”

NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility. As part of the Client-Partner relationship with Pivot Pharmaceuticals Inc., NNW will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the Company.

“Pivot Pharmaceuticals is preparing to commercialize an industry leading pipeline of cannabinoid-based consumer healthcare products,” states Sherri Franklin, director of Content Marketing for NNW. “We look forward to assisting the company with a corporate communications campaign that effectively keeps shareholders and the investment community up to date on its operations and technology.”

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com.

 About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$NETE Featured: Global Consumer Markets & Mobile Payment, Electronic Wallet Tech

MarketNewsUpdates.com News Commentary

Palm Beach, FL – (February 8, 2018) – The way consumers globally pay is changing. As shopping habits evolve, e-commerce and m-commerce methods such as in-app and one-click ordering are becoming increasingly popular. In addition, the exponential growth of the Internet of Things (IoT) is introducing a wealth of new payment use-applications. The promise of frictionless, secure transactions in real time from any payment device (be it a kiosk, smartphone, computer or payment terminal) is one that gives the consumer complete control over their purchasing experience. Electronic wallets and mobile ecommerce are continually gaining popularity due to rise of easy to use mobile apps while the market is driven by tech firms introducing new and secure devices & applications and by banks developing their own apps and providing on the go services for the customers. Active companies in the markets this week include Gopher Protocol Inc. (OTC: GOPH), Net Element, Inc. (NASDAQ: NETE), PayPal Holdings, Inc. (NASDAQ: PYPL), Alibaba Group Holding Limited (NYSE: BABA), Apple Inc. (NASDAQ: AAPL).
Gopher Protocol Inc. (OTCQB: GOPH), a development-stage company which specializes in the creation of Internet of Things (IoT) and Artificial Intelligence enabled mobile technologies, incorporates UGopherServices Limited in England and Wales.

With the incorporation of UGopherServices Limited, Gopher looks to expand its platform internationally. Since Gopher’s acquisition of RWJ Marketing’s assets and the incorporation of UGopherServices Corp. in the United States, Gopher has been approached by potential partners to provide services to international clientele. In order to maximize this international opportunity and shareholder value, Gopher established UGopherServices Limited, which was incorporated in England and Wales and will operate as a wholly owned subsidiary.

“We are looking to initially introduce our existing product and service offerings to clients internationally. As we further develop our offerings, such as an electronic wallet, in the United States we, we intend to offer these products internationally as well assuming there is a suitable fit” stated Gopher CEO Greg Bauer. Read this and more news for GOPH at: http://www.marketnewsupdates.com/news/goph.html

In other Mobile Payments and Digital Commerce developments in the markets this week:

Net Element, Inc. (NASDAQ: NETE), a global technology and value-added solutions group, this week launched its newest multi-channel payments platform, Netevia. Connecting and simplifying payments across sales channels through a single integration point, Netevia delivers end-to-end payment processing through easy-to-use APIs. This model complements Net Element’s ability to perform in a multi-channel environment, including point-of-sale (POS), e-commerce, mobile devices and will enable the company to perform in blockchain technology solutions.

A recent article on PYMNTS.com, PayPal’s “Global Freelancer Insights Report” found that mobile is an important tool for freelancers, while security is also top of mind. In a corporate blog post detailing the results, PayPal Holdings, Inc. (NASDAQ: PYPL) said mobile payments, mobile apps and mobile communication are important tools for freelancers, with those surveyed noting mobile tools and the ability to invoice and receive payments on mobile devices is crucial for them. Additionally, PayPal said security is a big concern for freelancers, with 47 percent of those surveyed saying security is an important factor when choosing a payment method. While PayPal’s survey found freelancers to be optimistic about their futures, they did admit an irregular income is their biggest challenge. Of the survey respondents, the majority of freelancers around the world expect business to grow in the future, with strong growth expected from those residing in Vietnam, India, the Philippines, Mexico and Argentina. At the same time, more than 50 percent of freelancers polled in Hong Kong, Russia and South Africa said irregular payments are an issue. Read the full article at: https://www.pymnts.com/news/mobile-payments/2018/paypal-freelancer-jobs-platforms/

MacRumors.com reported this week that Alipay, the mobile payment system offered by Chinese e-commerce giant Alibaba Group Holding Limited (NYSE: BABA), will soon be accepted in Apple retail stores across China, making it the first third-party mobile payment system to be accepted at brick-and-mortar Apple stores anywhere in the world (via Reuters). The partnership with Apple Inc. (NASDAQ: AAPL) was announced in a statement on Wednesday by Alibaba affiliate Ant Financial, which runs Alipay. Apple’s regional China website, iTunes Store, and App Store have accepted Alipay for over a year, but Apple has now agreed to accept Alipay payments across all of its 41 local retail stores in the country, where Apple Pay has thus far received a lukewarm reception. Read more at: https://www.macrumors.com/2018/02/07/apple-retail-stores-china-alipay-mobile-payments/

DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated twenty three hundred dollars for news coverage of the current press releases issued by Gopher Protocol Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information:
Media Contact email: info@marketnewsupdates.com – +1(561)325-8757

$DRYS Announces Dividend, Authorization of an up to $50 Million Stock Repurchase

ATHENS, Greece, Feb. 07, 2018 — DryShips Inc. (NASDAQ:DRYS)  (“DryShips” or the “Company”), a diversified owner of ocean going cargo vessels, announced today that, in accordance with its previously announced dividend policy, the Company’s Board of Directors has declared a quarterly cash dividend with respect to the quarter ended December 31, 2017.

With respect to the quarter ended December 31, 2017, the Board of Directors declared a cash dividend of $2.5 million payable on or about March 8, 2018 to common shareholders of record as of February 20, 2018. The dividend per share amount to be paid by the Company, based on the Company’s 104,274,708 common shares outstanding, will be approximately 2.4 cents per share.

The Company also announced today that its Board of Directors has authorized a stock repurchase program, under which the Company may repurchase up to $50 million of its outstanding common shares for a period of 12 months. DryShips may repurchase shares in privately negotiated or open-market purchases in accordance with applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The specific timing and amount of repurchases, if any, will be at the discretion of the Company’s management and will depend upon a variety of factors, including market conditions, regulatory requirements and other corporate considerations. The Company is not obligated under the program to purchase any shares.  Due to applicable securities laws, the Company’s repurchase of shares will not begin until after the release of the Company’s financial statements for the fourth quarter ending December 31, 2017, which is expected to be within February. The repurchase program may be suspended or discontinued at any time. The Company expects to finance the stock purchases with existing cash balances.

About DryShips Inc.

The Company is a diversified owner of ocean going cargo vessels that operate worldwide. The Company owns a fleet of 35 vessels comprising of (i) 12 Panamax drybulk vessels; (ii) 4 Newcastlemax drybulk vessels; (iii) 5 Kamsarmax drybulk vessels; (iv) 1 Very Large Crude Carrier; (v) 2 Aframax tankers; (vi) 1 Suezmax tanker; (vii) 4 Very Large Gas Carriers and (viii) 6 offshore support vessels, including 2 platform supply and 4 oil spill recovery vessels.

DryShips’ common stock is listed on the NASDAQ Capital Market where it trades under the symbol “DRYS.”

Visit the Company’s website at www.dryships.com

Forward-Looking Statement

Matters discussed in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with such safe harbor legislation.

Forward-looking statements reflect the Company’s current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond the Company’s control, the Company cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.

Important factors that, in the Company’s view, could cause actual results to differ materially from those discussed in the forward-looking statements include the factors related to the strength of world economies and currencies, general market conditions, including changes in charter rates, utilization of vessels and vessel values, failure of a seller or shipyard to deliver one or more vessels, failure of a buyer to accept delivery of a vessel, the Company’s inability to procure acquisition financing, default by one or more charterers of the Company’s ships, changes in demand for drybulk or LPG commodities, changes in demand that may affect attitudes of time charterers, scheduled and unscheduled drydockings, changes in the Company’s voyage and operating expenses, including bunker prices, dry-docking and insurance costs, changes in governmental rules and regulations, changes in the Company’s relationships with the lenders under its debt agreements, potential liability from pending or future litigation, domestic and international political conditions, potential disruption of shipping routes due to accidents, international hostilities and political events or acts by terrorists.

Risks and uncertainties are further described in reports filed by DryShips Inc. with the Securities and Exchange Commission, including the Company’s most recently filed Annual Report on Form 20-F. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. If one or more forward-looking statements are updated, no inference should be drawn that additional updates will be made.

Investor Relations / Media:

Nicolas Bornozis
Capital Link, Inc. (New York)
Tel. 212-661-7566
E-mail: dryships@capitallink.com

$VSQTF Enters Definitive Agreement to Acquire 31.35% of PayVida Solutions

Emerging payment processing company to join rapidly-expanding Victory Square portfolio

VANCOUVER, British Columbia, Feb. 07, 2018 — Subject to all requisite regulatory approvals, Victory Square Technologies Inc. (“Victory Square” or the (“Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) will acquire 31.35% percent of all issued and outstanding shares of PayVida Solutions Inc. (“PayVida”), an emerging payment processing company, for $1,900,000 CAD in total consideration (the “Purchase Price”).

Pursuant to a definitive subscription agreement to be executed between the Company and PayVida (the “Subscription Agreement”), the Purchase Price will be satisfied by cash installments totalling $1,250,000 (the “Cash Consideration”) by the Company and the issuance of $650,000 in value of common shares of the Company (the “Consideration Shares”). Cash Consideration will be payable in monthly increments until paid in full on April 1, 2018, and an aggregate 365,168 Consideration Shares, each at a deemed issue price of $1.78, shall be issued to PayVida. The deemed issue price represents the closing price of the common shares of the Company on the Canadian Securities Exchange at the end of trading on February 6, 2018, the trading day preceding this news release announcing the proposed acquisition, less a discount of 15%. In accordance with the terms of the Share Purchase Agreement, the Consideration Shares shall be subject to resale restrictions, which permit 8% of the Consideration Shares to be eligible to be free-trading four months from the date of issuance to satisfy the statutory hold period and a further 8% every three months thereafter until the final balance of Consideration Shares is eligible to be free-trading in approximately three years’ time. The Subscription Agreement also contains standard representations, warranties and covenants for transactions of this nature. The transaction remains subject to all requisite regulatory approvals.

The payment processing innovator was appealing to Victory Square given its role in promoting the highest standards in ethics and technology in the payment processing industry worldwide.

“PayVida provides solutions that challenge the existing technologies that most banks and payment processing providers offer,” said Victory Square Chief Executive Officer Shafin Diamond Tejani. “They have established themselves by offering less expensive pricing and same-day funding times that merchants have never experienced with today’s leading FinTech giants.”

PayVida will be launching its global payment facilitator platform that will enable merchants and their staff to receive same day funding of daily credit and debit card transactions, tips and related payouts on PayVida’s branded MasterCard ® accepted worldwide.

“Fellow co-founder Ryan Strauss, myself and the rest of our hardworking team are very excited to announce that we have closed our financing deal with Victory Square Technologies,” said Robert Ronning, co-founder of PayVida. “For the last few years, the Victory Square team has guided our progress and Shafin Diamond, as CEO, has always been gracious with his counsel and advice over that time. We are truly honoured and humbled to have this chance to deepen our relationship with all the excellent thought leaders at Victory Square.”

PayVida’s payment acceptance and card issuance platform enables merchants, ISOs and channel partners with prepaid card issuance, instant ECommerce, Restaurant, Retail and Mobile smart terminal activations that are fully EMV and NFC card ready.

“PayVida provides a key opportunity for Victory Square to invest in leading technology companies in a number of different verticals and provide them with the tools necessary to accelerate their growth,” added Tejani. “Through our venture builder model, we are able to identify great candidates for growth and provide them with expertise in a number of functional areas such as product enhancements, sales strategy, go to market, and customer retention to name a few. This type of value add has allowed us to not only attract quality companies, but has provided us the privilege of building a world class portfolio of companies ripe to emerge as leaders in their respective industries.”

Tejani noted that for the duration of 2018, Victory Square will continue to foster and grow its portfolio companies while looking to deploy additional capital in attractive and undervalued assets.

“A key part of our venture build model requires liquidity events in order to enhance the intrinsic value of Victory Square,” explained Tejani. “We will be pursuing value realization strategies for some of our portfolio holdings that may come in the form of IPOs, RTOs or outright sales.”

For further information about the Company, please contact:

Investor Relations Contact – Prit Singh
Email: ir@victorysquare.com
Telephone: 905-510-7636

Media Contact – Howard Blank, Director
Email: howard@victorysquare.com

Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square Technologies is a blockchain-focused venture builder that funds and empowers entrepreneurs to implement innovative blockchain solutions. Victory Square portfolio companies are disrupting every sector of the global economy including Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. Victory Square has a proven process for identifying game-changing entrepreneurs and providing them with the partners, mentorship and support necessary to accelerate their growth and help them scale globally. For more information, please visit www.victorysquare.com.

ABOUT THE CANADIAN SECURITIES EXCHANGE (CSE)
The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets.

FORWARD-LOOKING INFORMATION
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Victory Square. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square, including future plans. Although Victory Square believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Victory Square can give no assurance that they will prove to be correct. Forward- looking statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

$NETE Launches Future-Ready Multi-channel Payments Platform, Netevia

Netevia to provide same business-day settlement and funding for merchants

MIAMI, FL, Feb. 07, 2018 — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group, today launched its newest multi-channel payments platform, Netevia. Connecting and simplifying payments across sales channels through a single integration point, Netevia delivers end-to-end payment processing through easy-to-use APIs. This model complements Net Element’s ability to perform in a multi-channel environment, including point-of-sale (POS), e-commerce, mobile devices and will enable the company to perform in blockchain technology solutions.

Netevia will form part of the recently announced decentralized blockchain technology solutions that enable an unlimited number of value-added services (“VAS”) to connect merchants and consumers via blockchain technology, while increasing economic efficiency of all transactions being made within the ecosystem. With new features to be implemented on the platform, Netevia plans to disrupt everyday commerce.

Netevia features a user-friendly developer center with language-agnostic APIs, SDKs and sandbox for testing. Netevia is fully integrated with major payments platforms and smart payment terminals that allow merchants to accept most payment methods in multiple currencies internationally. A flexible payments hub makes it easy and fast to add new features and services as payment needs evolve.  Additional security and fraud prevention options within the Netevia platform include more than 150 risk monitoring filters, vaulting, tokenization and point-to-point encryption which reduce the PCI DSS scope and help minimize compliance burden.

Integrations with major payments platforms make it possible for merchants and developers to integrate payment acceptance into everyday commerce through easy to use APIs, no matter what device is being used. Instant merchant on-boarding, same business day settlement and funding, as well as value-added features such as gift and loyalty business solutions drive repeat business and increased sales. Payment conversion and smart-routing optimization help merchants reach up to 99.2% conversion rates, which translate into increased revenues. This transparent, turn-key solution with low processing fees is available with no setup, monthly or hidden fees. Visit www.netevia.com for more information.

“Netevia was designed by developers with developers in mind,” commented Andrey Krotov, Net Element’s chief technology officer. “We put together all the building blocks needed for developers and merchants to integrate payments into their everyday commerce. The Netevia platform delivers a blueprint and easy to use tools for global commerce and monetization, saving developers and merchants time and money with one provider and one integration across all sales channels.”

About Net Element
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. In the U.S. it aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, our cloud based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500™.  In 2017 we were recognized by South Florida Business Journal’s as one of 2016’s fastest growing technology companies. Further information is available at www.netelement.com.

Forward-Looking Statements
Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to the timing of completion of new features for the platform, whether contemplated projects and the utilization of blockchain technology will be successful, whether the addition of blockchain technology-focused payment processing solutions business will indeed become a framework for multiple value-added services, whether the features on the platform will disrupt everyday commerce, whether the Company will be successful in expansion and growth endeavors; and even if it is successful in any or all of these endeavors, whether this will positively impact the Company or result in improved shareholder value. Additional examples of such risks and uncertainties are: (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Net Element, Inc.
1-786-923-0502
media@netelement.com

$ETST Eyes Uplisting to OTCQB, Retains Counsel

February 7, 2018

• Goal is to raise $4 million to help company finance its planned projects
• Expansion into Canada eyed, attorney retained to help seek Canadian licenses to import ETST’s CBD-rich hemp oil into country
• ETST would also use funding for MSN-2, its home kit for the detection of sexually transmitted diseases

Earth Science Tech, Inc. (OTC: ETST) is working toward an uplisting to the OTCQB Venture Market in early 2018. It has also retained counsel for a planned Regulation A+ Tier 2 round of financing, which the company hopes will raise an aggregate of $4 million (http://cnw.fm/W8I2d). The funds would be used to finance its planned projects in the new year and for general working capital (http://cnw.fm/Pi0hl), with share cancellation by company founders counteracting dilution.

ETST is also eyeing expansion into Canada in 2018, and it has appointed an attorney who will serve as consultant for ETST’s activities in that country, Avi Levi, Esq. (http://cnw.fm/aW8ww). He will help the company apply for licenses to import its CBD-rich hemp oil into Canada. It will then be exported to various countries as raw hemp oil or in individual ready-to-consume bottles, the company said.

Dr. Michel Aube, CEO and chief scientific officer of the company, said, “With the funds being raised through the Regulation A+ offering, we will be in a position to begin finalizing all of our projects while we pursue grants from the Canadian government to cover our MSN-2 medical device, CBD patent pending formulas and CBD based generic pharmaceutical drugs.”

The MSN-2 device is prepared for third-party evaluation ahead of manufacture and commercialization. The MSN-2 device is a home kit designed for the detection of sexually transmitted diseases.

ETST is a biotechnology company operating in the fields of hemp cannabinoid pharmaceutical, nutraceutical, and medical device R&D. Its hemp CBD is made using the liquid extraction process. As a result, its CBD oil is 100 percent natural and organic, as noted by the company.

ETST has three wholly owned subsidiaries. First, Earth Science Pharma, Inc. specializes in the development of medical devices for the treatment of sexually transmitted diseases. Second, Cannabis Therapeutics, Inc. works to explore the medicinal powers of CBD. Cannabis Therapeutics holds a provisional application patent for a CBD product which develops treatments for ovarian and breast cancers. Third, KannaBidioid, Inc. focuses on the recreational cannabis space.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

• EVIO, Inc. (EVIO) is Exceeding Expectations
• Recent Report on PotNetwork Holding Inc. (POTN) Share Price Target Highlights Encouraging Data
• Teewinot Life Sciences’ Patented Biosynthetic Tech Cuts Costs and Produces Clinical-Grade Cannabinoids

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

$ATAI Definitive Agreement Sale of Wholly-owned Subsidiary ATA Online

Company Intends to Utilize Public Company to Develop Existing Technologies and Explore Acquisition Opportunities

BEIJING, Feb. 06, 2018 — ATA Inc. (“ATA” or the “Company”) (Nasdaq:ATAI), a leading provider of advanced testing technologies and testing-related services in China, today announced that it has entered into a share purchase agreement (the “Share Purchase Agreement”) with a group of investors including two entities affiliated with funds managed by CDH Investments, a major Chinese alternative asset management firm based in Beijing; New Beauty Holdings Limited, a company controlled by ATA’s Chairman and Chief Executive Officer Mr. Kevin Xiaofeng Ma; and four holding companies controlled by certain management members of ATA’s wholly-owned subsidiary ATA Online (Beijing) Education Technology Co., Ltd. (“ATA Online”) (collectively, the “Buyer Group”), with respect to the sale of ATA Online. For the fiscal year ended March 31, 2017, ATA Online contributed approximately 98% of ATA’s revenue and nearly 100% of positive bottom line contribution. The Company has also filed a Form 6-K containing additional information, which investors may access on the SEC Filings page on ATA’s website or on the U.S. Securities and Exchange Commission website at www.sec.gov.

No vote of ATA’s shareholders is required or will be conducted to approve the transactions contemplated by the Share Purchase Agreement.

Terms of the Share Purchase Agreement/Expected Closing Date
Under the terms of the Share Purchase Agreement, the Buyer Group has agreed to acquire all of the outstanding equity interests of ATA Online, which is currently held directly or indirectly by ATA for a total consideration of US$200 million in cash (the “Transaction”). The US$200 million in cash consideration payable by the Buyer Group for ATA Online represents an 87.4% premium over ATA’s market capitalization (calculated based on the closing trading price of ATA’s ADSs on February 5, 2018).

Mr. Ma will pay a cash deposit in the amount of US$20 million to ATA as collateral and security for the payment obligations of the Buyer Group under the Share Purchase Agreement.

The closing of the Transaction is expected to take place in three stages subject to the satisfaction of various conditions precedent in the Share Purchase Agreement. The first of the three closings is expected to take place within 30 business days after the date of the Share Purchase Agreement, and the Company expects the Transaction to be completed in the third quarter of 2018. The Company will continue to provide updates throughout the process but cautions investors that there are no assurances that all of the conditions for the closing stated in the Share Purchase Agreement will be satisfied or that the Transaction will ultimately be completed.

Background on Share Purchase Agreement
As previously announced, in August 2017 ATA’s Board of Directors formed a special committee (the “Special Committee”) comprised of two independent directors, Alec Tsui and Hope Ni, to evaluate the Transaction. The Special Committee, with the assistance of its financial advisor Duff & Phelps Securities, LLC and Duff & Phelps, LLC, (collectively, “Duff & Phelps”), and its U.S. legal counsel Morgan, Lewis & Bockius LLP, exclusively reviewed and negotiated the terms of the Transaction with the Buyer Group. As part of this process, the Special Committee conducted a market check for the Transaction with other potential buyers, which included six potential strategic buyers and 10 potential financial buyers, with no competing proposal being submitted to the Special Committee as of the end of the two-month market check period and as of the date hereof. The Special Committee also successfully negotiated an increase in total price consideration to US$200 million from the originally proposed US$150 million.

On February 6, 2018, the Special Committee unanimously resolved to approve the Share Purchase Agreement and the Transaction, and recommended that the Board of Directors approve the proposed Share Purchase Agreement and the Transaction. On February 6, 2018, the Board of Directors, acting upon the unanimous recommendation of the Special Committee, approved the Transaction, the Share Purchase Agreement and related transaction documents.

The Board’s Plans for ATA Following the Transaction
If the Transaction is completed, ATA will no longer conduct its testing development and delivery business currently operated by ATA Online.

The remaining portion of ATA’s business includes the following: (i) the business in development of K-12 education assessment tools and content (ii) the Nanjing University Project Shuang Chuang, (iii) the Research Project with the Education and Research Institute of Tsinghua University, and (iv) minority investments in Beijing Empower Education Online, Co., Ltd., ApplySquare Education & Technology Co., Ltd., Beijing GlobalWisdom Information Technology Co., Ltd., Brilent, Inc., Beijing Satech Internet Educational Technology Ltd. and Master Mind Education Company.

Following the closing of the Transaction, ATA intends to focus on its assessment content and instrument development businesses in K-12 and higher education areas. The Company intends to use the proceeds received from the Transaction to fund one or more of the following items: (1) potential merger and acquisition targets in the education sector; (2) the development and expansion of its retained business in assessment content and instruments development in K-12 and higher education areas; (3) support of the Nanjing University and Tsinghua University projects; and/or (4) dividends to its shareholders.

ATA’s reporting obligations as a SEC-registered public company will not be affected as a result of the consummation of the Transaction. ATA will continue to work to maximize shareholder interests with a goal of returning value to its shareholders.

Shareholder Information Relating to the Transaction
To share value with ATA’s shareholders, ATA’s Board of Directors has preliminarily approved to use a portion of the proceeds received from the Transaction to pay a cash dividend to the shareholders, subject to compliance with Cayman Islands and PRC laws. However, the timing and amount of any cash dividend have not been decided, and may vary depending on several factors, including the progress of the Transaction, funding need for ATA’s remaining businesses and mergers and acquisitions plans, as well as any contingent liabilities or other unforeseen matters.

The sale of ATA Online will not alter the rights, privileges or nature of the issued and outstanding shares (“Shares”). A shareholder who owns ATA’s Shares or ADSs immediately prior to the closing of the Transaction will continue to hold the same number of Shares or ADSs immediately following the closing.

About ATA Inc.
ATA is a leading provider of advanced testing technologies in China. The Company offers comprehensive services for the creation and delivery of assessments based on its proprietary testing technologies and test delivery platform. ATA’s testing technologies are used for professional licensure and certification tests in various industries, including information technology services, banking, teaching, asset management, insurance, and accounting. As of September 30, 2017, ATA’s test center network comprised 3,256 authorized test centers located throughout China. The Company believes that it has the largest test center network of any commercial testing service provider in China.

ATA has delivered a total of approximately 93.4 million billable tests since ATA started operations in 1999. For more information, please visit ATA’s website at www.atai.net.cn.

For more information on our company, please contact the following individuals:

At the Company
ATA Inc.                                                                                                                  .
Amy Tung, Chief Financial Officer
+86 10 6518 1122 x5518
amytung@atai.net.cn

Investor Relations
The Equity Group Inc
Carolyne Y. Sohn, Senior Associate
415-568-2255
csohn@equityny.com

Adam Prior, Senior Vice President
212-836-9606
aprior@equityny.com

$INPX Effects Reverse Stock Split

PALO ALTO, Calif., Feb. 06, 2018 — Inpixon (NASDAQ:INPX), a leading indoor positioning and data analytics company, today announced that the Company’s Board of Directors has approved a reverse stock split of the Company’s common stock whereby every thirty (30) shares of common stock will automatically be combined into one (1) share of common stock. The reverse split was approved by the Company’s shareholders on February 2, 2018 and will be effective as of the commencement of trading on February 6, 2018.

About Inpixon

Inpixon (NASDAQ:INPX) is a leader in Indoor Positioning and Data Analytics. Inpixon sensors are designed to find all accessible cellular, Wi-Fi, and Bluetooth devices anonymously. Paired with a high performance, data analytics platform this technology delivers visibility, security, and business intelligence on any commercial or government premises world-wide. Inpixon’s products, infrastructure solutions, and professional services group help customers take advantage of mobile, big data, analytics, and the Internet of Things (IoT) to uncover the untold stories of the indoors. For the latest insight on Indoor Positioning and Data Analytics, follow Inpixon on LinkedIn and @InpixonHQ on Twitter.

Safe Harbor Statement

All statements in this release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of Inpixon and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and employees, the Company’s ability to obtain financing, competition, general economic conditions and other factors that are detailed in the Company’s periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements.

Contacts:

Inpixon Investor Relations:
CORE IR
Scott Arnold, +1-516-222-2560
Managing Director
www.coreir.com

$NETE Poised for Organic Growth in 2018

February 6, 2018

• Net Element is looking forward to continued growth in 2018
• 2017 held a number of accomplishments, including the company’s strongest balance sheet and a $7.55 million investment
• Over the past year, Net Element has produced important product launches in the U.S. and internationally

Net Element, Inc. (NASDAQ: NETE) is looking forward to continual development and delivery of innovative payment solutions in 2018 and beyond. According to a recent press release (http://nnw.fm/8aDOe), last year provided the company with its strongest balance sheet on record. In 2017, Net Element re-focused business initiatives internationally and saw organic growth across all categories. In a news release, CEO Oleg Firer said that the company’s leadership team is very pleased with the progress made and looks “forward to significant accomplishments in 2018 to include the addition of blockchain technology that will act as a framework for an unlimited number of value-added services.” According to Firer, the future looks promising as the company remains focused on the execution of its long-term objective “to create a single, international on-boarding and transaction processing platform across payments ecosystems.”

In 2017, the company received a $7.55 million institutional investment, supporting continued organic growth and ensuring full scalability of its platform, as well as blockchain-focused developments. Deloitte’s 2017 Technology Fast 500™ ranked Net Element as one of the fastest-growing companies in North America. The year before, 2016, South Florida Business Journal ranked Net Element as one of the fastest-growing technology companies. When Hurricane Irma hit, the company was ready and able to support affected Florida SMB merchants with free mobile point-of-sale credit card readers.  Net Element works to provide virtually seamless payment solutions and powerful problem-solving expertise to the small to medium enterprises it serves. The $7.55 million investment has put the company in position to continue achieving organic growth as it moves forward with innovative blockchain developments.

The company competes in highly competitive market segments using innovative technology at the core of its products. In 2017, Net Element launched several successful products to better the user experience. The products launched exclusively in the United States included a same-day ACH payment processing solution, a zero-fee processing program for SMB merchants and PayOnline’s support for electronic commerce. In Russia, the company launched Apple Pay support. Additional product launches included loyalty programs for merchants; a payment acceptance module for Telegram, Viber and Facebook; VK instant messenger apps; a comprehensive point-of-sale program during Unified Payments’ 2017 Launch Series at the Northeast Acquirers Association event; and an ISO incubator program for certified resellers of Unified Payments. NETE also expanded payment modules to include Prominent InSales.

Net Element has goals in the United States and internationally. In the U.S., it seeks to grow transactional revenue. By using blockchain technology and Aptito, a cloud-based, restaurant and retail point-of-sale solution, the company aims to grow transactional revenue. Internationally, it leverages an omni-channel platform, delivering flexible offerings to emerging markets.

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

• EVIO, Inc. (EVIO) is Exceeding Expectations
• Recent Report on PotNetwork Holding Inc. (POTN) Share Price Target Highlights Encouraging Data
• Teewinot Life Sciences’ Patented Biosynthetic Tech Cuts Costs and Produces Clinical-Grade Cannabinoids

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$NETE Reflects on 2017 Milestones, Looks Ahead to 2018

February 5, 2018

• Company’s balance sheet is currently the strongest it has ever been
• Named one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500™
• Total transaction dollars processed by the company during 2017 reached $2.8 billion

Looking back on 2017 and ahead to the continuation of 2018, Net Element, Inc. (NASDAQ: NETE) CEO Oleg Firer recently sent out a letter to shareholders discussing the company’s progress and developments that have occurred over the past year (http://nnw.fm/yv1HJ).

Net Element is a global technology and value-added solutions group operating a payments-as-a-service transactional and value-added services platform for small to medium enterprise in the United States and in select emerging markets. The company supports electronic payments acceptance in a multi-channel environment, including point-of-sale, e-commerce, mobile devices and the blockchain ecosystem.

On an international level, Net Element is focused on leveraging its omni-channel platform to provide flexible solutions to emerging markets that have varied banking, regulatory and demographic circumstances.

All around, 2017 was a banner year for Net Element. The company was named one of North America’s fastest-growing companies on Deloitte’s 2017 Technology Fast 500™, and Net Element was also named one of the fastest-growing technology companies of the year by South Florida Business Journal.

Throughout 2017, Net Element moved forward with its organic growth in the United States, focusing on value-added payments solutions. The company was successful in centralizing its operations and refocusing its business initiatives on a global level.

For the year, total transaction dollars processed by Net Element amounted to $2.8 billion, while total transaction dollars processed geographically in North American and international markets were, respectively, $2.35 billion and $446 million.

Also during 2017, Net Element received a $7.55 million institutional investment to further its ongoing organic growth and blockchain-centered developments. The company additionally gave free mobile point-of-sale card readers to SMB merchants in Florida that were affected by Hurricane Irma.

Net Element further forged various partnerships in 2017, partnering with companies like Elo, Payvision and Planet Payment and also launching services for V-Tell, Azimuth Airlines and iDEAL.

Various product launches were further achieved by the company during 2017, including:

• Same-day ACH payment processing solution in the U.S.
• Zero-fee processing program for SMB merchants in the U.S.
• Loyalty program for merchants
• PayOnline’s support for e-commerce in the U.S.
• Apple Pay support in Russia
• Payment acceptance module for Telegram, Viber, Facebook and VK instant messenger apps
• Expansion of payments module to include Prominent InSales
• Comprehensive point-of-sale program
• ISO incubator program for certified resellers of Unified Payments

The global payments industry continued to thrive during 2017, and Net Element looks forward to even more opportunities to develop pioneering payment solutions in the coming year and further into the future as disruptive technologies like blockchain continue to advance. Heading into 2018, Net Element is bolstered by the strongest balance sheet it has ever had, positioning the company for growth and a strong stance from which to execute on exciting opportunities.

Looking ahead, Net Element plans to add blockchain technology during 2018, which will act as a framework for a huge array of value-added services. The company will also continue its focus on executing the long-term goal of creating a single, international onboarding and transaction processing platform that spans payments ecosystems.

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

• ChineseInvestors.com, Inc. (CIIX) Offering Innovative Access to Cryptocurrency
• Skinvisible, Inc. (SKVI), Quoin Pharmaceuticals Proposed Merger to Address Opioid Pain Management Market
• PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Developing Alternative Solutions in Health-Boosting Market

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$DJACF Licensed Cannabis Producer Receives Notification of Pre-Sales Inspection

TORONTO, Feb. 5, 2018 – Hiku Brands Company Ltd. (“Hiku” or the “Company“) (CSE: Hiku), Canada’s first vertically-integrated cannabis brand house, is pleased to announce its wholly owned subsidiary DOJA Cannabis Ltd. (“DOJA“), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”), received notification from Health Canada that the company’s pre-sale inspection has been scheduled for Tuesday, February 13, 2018. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the ACMPR.

“As there are currently only 26 independent companies with cannabis sales licenses under the ACMPR in Canada, receiving confirmation of our Pre-Sales License Inspection from Health Canada is a major milestone for Hiku. I’m extremely proud of our cultivation team, the dedication to their craft shows in the very high-quality flower being produced at our licensed facility. Our team’s ability to execute has allowed us to advance to the Pre-Sales License Inspection ahead of schedule and faster than our peers. We look forward to soon selling DOJA-branded cannabis to our valued customers,” said Alan Gertner, CEO of Hiku.

About Hiku

Hiku is focused on handcrafted cannabis production, immersive retail experiences, and building a portfolio of iconic, engaging cannabis lifestyle brands. Hiku is differentiated as the only Canadian craft cannabis producer with a significant national retail footprint and a growing brand house including premium cannabis lifestyle brands DOJA, Tokyo Smoke, and Van der Pop.

Hiku’s wholly-owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

Hiku has entered into supply partnerships with Aphria Inc. (“Aphria“) (TSX: APH) (OTCQB: APHQF) and WeedMD Inc. (TSXV: WMD) (“WeedMD“) to ensure Hiku’s brands will be able to scale in 2018 and beyond.

About Aphria

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. Aphria was the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.

About WeedMD

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of medical cannabis under the ACMPR. The Company operates an indoor facility in Aylmer, Ontario, and is awaiting its second-site cultivation license for its greenhouse facility located in Strathroy, Ontario. WeedMD has entered into supply agreements in addition to strategic relationships with established cannabis brands. WeedMD is focused on providing medical cannabis to the long-term care, assisted living and seniors’ markets in Canada through its specialized and comprehensive platform. It is dedicated to educating healthcare practitioners and furthering public understanding of the role that medical cannabis plays – including as it pertains to regulatory requirements, indications and potential side effects.

Statement Regarding Forward-Looking Information

This news release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include the Company’s expectation that it will sell DOJA-branded products to customers, and scale in 2018 and beyond. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.